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ABSTRACT 
 
Canine acute pancreatitis (AP) is commonly encountered in veterinary clinical practice. Acute 
pancreatitis can occur on its own as a primary disease or can be secondary to other diseases. 
Early recognition and appropriate management of dogs with AP can be hampered by difficulty in 
not only diagnosing the disease, but also differentiating primary versus secondary pancreatitis. 
Failure to recognise that AP is actually the result of another underlying disease may lead to 
inappropriate management of the patient. This is especially important in critically ill dogs that 
present to an emergency service.  
 
Historically, catalytic assays have been used to diagnose AP but the tests have shown poor 
reliability. These tests have largely been criticised for lack of sensitivity and specificity, as 
pancreatic enzyme activity may not solely represent pancreatic leakage. Recently, a laboratory-
based canine specific pancreatic lipase test (Spec cPL
®
) has been developed to aid diagnosis 
of AP, which is specific to the detection of pancreatic lipase leakage. To date, there are few 
studies evaluating the Spec cPL
®
, but it was developed in the hope it would provide a more 
definitive diagnosis of AP. Questions have been raised as to its accuracy as a diagnostic test, 
and it still does not differentiate between primary and secondary pancreatitis.  
 
An in-house canine pancreatic lipase test (SNAP
®
 cPL) has also become available to clinicians. 
The manufacturer has reported very good agreement between the Spec cPL
®
 and SNAP
®
 cPL, 
using recombinant canine pancreatic lipase (cPL), but this is yet to be tested clinically. The first 
aim of this study therefore was to measure agreement between these two tests in dogs 
presenting with clinical signs of acute abdominal disease. The second aim was to determine the 
degree of agreement (if any) between a clinical diagnosis of primary AP and increased cPL 
concentration, as measured by the above two tests. The third aim was to establish the 
sensitivity and specificity for these tests in dogs with clinically diagnosed primary AP.  
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The results of this study demonstrated that the SNAP
®
 cPL and Spec cPL
®
 tests had good 
agreement with each other for the entire cohort of dogs. However, there was poor agreement 
between each of these tests and a clinical diagnosis of pancreatitis. While sensitivity did not 
differ markedly from previous reports on Spec cPL
®
, specificity results were much lower. 
Therefore, it appears that these tests can detect the presence of cPL but cannot be used in 
isolation to diagnose primary pancreatitis. 
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CHAPTER 1: INTRODUCTION AND OVERVIEW 
Canine pancreatitis, in all its forms, has remained an area of intense research for decades and it 
is likely to continue to generate much debate and research in this decade and the next. Many 
diagnostic tests have been suggested as important for the investigation of canine pancreatitis.  
However, no single test to date has been demonstrated to clearly possess a high sensitivity and 
many suffer poor specificity. Much of the research focusing on singular tests lacks a comparison 
to a ‘gold standard’. Obtaining diagnostic material for the gold standard test of pancreatitis is 
also problematic given the invasiveness necessary for pancreatic histology. In addition, despite 
the publication of studies comparing the test under investigation to a gold standard, there now 
appears to be emerging discord among researchers as to the accuracy of the gold standard 
diagnosis of pancreatitis itself (Mansfield et al., 2012). This could potentially confound 
interpretation of previous research and prohibit meaningful meta-analysis of studies concerned 
with the diagnosis of pancreatitis. 
  
A non-invasive, cheap, sensitive and specific cage-side test in the emergency setting is 
desirable for detection of canine pancreatitis, a disease which can present with non-specific 
clinical signs (Hess et al., 1998). Therefore, detection of pancreatic lipase has recently been 
posited as an important diagnostic tool for canine pancreatitis as this enzyme is specific to the 
pancreas (Steiner et al., 2006; Steiner et al., 2008). The canine pancreas-specific lipase (Spec 
cPL
®
) laboratory test designed to do this often requires a 24 hour wait for the result, potentially 
delaying timely and specific intervention required for non-pancreatic disease. The new SNAP
®
 
cPL is a cage-side test designed for immediate assessment, and can later be verified with the 
Spec cPL
®
. 
 
Over-reliance on these tests by clinicians, particularly in isolation, can lead to misdiagnoses. A 
plethora of research on the methods for diagnosis of pancreatitis in dogs has been published 
over a period of decades utilising various cohorts and methodologies. Discerning both the most 
useful and most relevant information from this body of research is challenging. Consequently, 
the interpretation of the clinical utility of these diagnostic tests may be subject to 
misconceptions. The canine specific pancreatic lipase assays (Spec cPL
®
 and SNAP
®
 cPL) 
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were developed to directly detect the presence of pancreatic lipase, and not just the activity of 
lipases in general (Steiner et al., 2002, Steiner et al., 2003). These tests initially appeared to 
offer an exciting development, garnering much interest amongst veterinary clinicians. However, 
most of the research conducted on these nascent tests has not applied stringent diagnostic 
guidelines, as discussed in Chapter 2, therefore raising questions about their accuracy. For 
example, some cohorts of dogs under study have included individuals that, by some standards, 
would not be considered suitable candidates for these tests in the clinical setting (see Chapter 
2).  
 
The prevalence of primary acute canine pancreatitis, as well as its presence as a co-morbid 
process in a range of canine diseases, remains unknown. The Spec cPL
®
 and SNAP
®
 cPL have 
been available worldwide for several years, and as more data is generated from their clinical 
use, more questions arise. Anecdotal communication between the author and many veterinary 
clinicians has revealed frustration; some veterinarians report dogs testing positive for increased 
pancreatic lipase, which then had final diagnoses that required specific intervention for diseases 
other than pancreatitis. Initially it was thought that measuring pancreatic lipase would be the 
silver bullet for diagnosis, as this enzyme is unique to the pancreas. However, the clinical 
significance of canine pancreatic lipase elevations as a sole marker for primary pancreatitis 
should be approached with caution given pancreatic inflammation can occur secondary to other 
pathologic processes. Although veterinary practitioners should consider all potential diagnoses 
for dogs with appropriate clinical signs, over-reliance on a diagnosis of primary pancreatitis, 
based on these tests, could decrease recognition of a co-morbid disease. Failure to recognise a 
potentially devastating underlying disease could have a severe, or even fatal, outcome for the 
patient, and prove financially onerous for the owner.  
 
The volume of published information available; the often conflicting nature of this information; 
and the ever-changing nature of the investigation of acute canine pancreatitis, demands a 
comprehensive review of the literature.  Therefore, the first objective of this thesis was to 
provide a robust and comprehensive review of the literature surrounding acute canine 
pancreatitis, focussing particularly on its diagnosis.  
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The second objective was to determine the sensitivity, specificity and accuracy of the SNAP
®
 
and Spec cPL
®
 tests in dogs presenting with acute abdominal disease to an emergency centre.  
The study undertaken here differs from previous investigations of these tests. Previous research 
has used pancreatic histopathology that could only be gained post-mortem, and correlated the 
changes with certain blood markers, such as canine pancreatic lipase. This limits the cohort of 
dogs under study to those that have died of their disease, or were euthanased, and often the 
latter predominates. In many dogs in these reports, the reason for euthanasia was not reported, 
or included shelter dogs. The determination of sensitivity and specificity of a diagnostic test 
should include a subpopulation of dogs representative of the greater population that are 
suspected of having the disease in question. Canine pancreatitis often presents with non-
specific signs which include vomiting, anorexia, and abdominal pain. It was the intention of this 
study to include dogs presenting with signs consistent with acute pancreatitis in order to assess 
the accuracy of canine pancreatic lipase in a representative clinical cohort. 
 
The third objective of this thesis was to quantify the agreement between the SNAP
®
 and Spec 
cPL
®
 tests using paired serum samples taken from dogs in the cohort described. The newer 
point-of-care SNAP
®
 cPL test has been investigated in only one recent publication and its 
agreement with the laboratory Spec cPL
®
 was not independently verified. The two tests utilise 
different methodologies applying the same basic principles. It is important to establish that these 
tests are indeed measuring the same target enzyme, in order to validate the point-of-care 
results. 
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CHAPTER 2: REVIEW OF THE LITERATURE – CANINE ACUTE 
PANCREATITIS 
 
2.1 Introduction 
 
Acute abdominal disease is usually defined as severe abdominal pain of less than 24-hours 
duration. Dogs that present to a veterinarian with acute abdominal disease require timely 
intervention. After initial clinical evaluation, it is vital to differentiate between medical and 
surgical cases early in the management process as this may have a significant effect on 
outcome. This differentiation can be difficult given that the choice of diagnostic tests is often 
limited in the emergency setting and the history, clinical examination and routine laboratory 
abnormalities can be non-specific. In cases of acute pancreatitis, the majority of dogs can be 
managed successfully medically (Thompson et al., 2009). Inappropriate surgical intervention 
can be costly and may increase morbidity and mortality. But, as noted in the previous chapter, 
accurate diagnosis of acute pancreatitis has proven challenging over the years. This thesis will 
focus on acute pancreatitis and current diagnostic testing and will not attempt to characterise or 
contrast this acute process with chronic pancreatitis. 
 
There are practical limitations associated with research into the diagnostic process for acute 
pancreatitis. There remain many areas where a consensus has yet to be reached, including 
determination of the most appropriate “gold standard” test and also the most accurate point-of-
care (POC) diagnostic test for this disease.  The patient history, clinical examination findings 
and routine clinical pathology in canine acute pancreatitis are often non-specific; hence there is 
a need for a simple cage-side test that provides a rapid and reliable diagnosis. Enzyme-linked 
immunosorbent assay (ELISA) tests have been developed for this purpose by Idexx 
Laboratories (Westbrook, Maine, USA). The test originally devised was the canine pancreatic 
lipase immunoreactivity (cPLI), however, the commercial application demanded a more efficient 
and cost effective method. The quantitative Spec cPL
®
 and then the semi-quantitative point-of-
care (POC) SNAP
®
 cPL were developed, which utilise the same capture and detection 
antibodies. However, research focused on the sensitivity and specificity of these tests has 
indicated that they may have limited clinical usefulness as sole diagnostic tests for acute 
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pancreatitis (Steiner et al., 2001; Steiner et al., 2008; Trivedi et al., 2011; McCord et al., 2012; 
Mansfield et al., 2012).  
 
2.2 Definition of Acute Pancreatitis 
In people, acute pancreatitis has been defined as an acute inflammatory or necrotising process 
of the pancreas that does not permanently disrupt the pancreatic architecture and has variable 
systemic complications, including death (Bradley 1993). Histological changes in canine acute 
pancreatitis primarily include the presence of neutrophils in the pancreas or peripancreatic fat 
without evidence of fibrosis or exocrine pancreatic atrophy (Newman et al., 2006). Acute 
pancreatitis may vary from mild to severe forms, such as acute necrotising pancreatitis, which is 
characterised by substantial pancreatic and peri-pancreatic necrosis (Feldman et al., 1981). 
This severe form can lead to necrosis of pancreatic acinar tissue and systemic complications, 
including multiple organ failure and, frequently, death of the dog (Mansfield et al., 2003). 
 
Other underlying diseases, such as those causing inflammation regional to the pancreas, can 
also cause acute pancreatitis (Frossard 2008). For the purpose of this thesis, this sort of acute 
pancreatitis is defined as secondary pancreatitis, as opposed to primary pancreatitis where an 
underlying cause is not identified.  
 
2.3 Aetiology and Risk Factors 
The precise cause of canine pancreatitis in the majority of cases is usually unknown and 
therefore most are considered to be idiopathic (Hess et al., 1998; Watson 2004; Steiner 2010).  
Many risk factors for the development of acute pancreatitis have been investigated yet most of 
these associations remain tenuous at best. 
 
Signalment of the patient is considered an important risk factor. In a necropsy study examining 
breed disposition for the development of pancreatitis, a total of 151 pancreata of dogs from first 
opinion practices were sequentially examined, after autolysed cases were removed from the 
analysis. Three histological sections from each dog were examined for evidence of pancreatic 
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pathology. Cavalier King Charles Spaniels, Collies, and Boxers showed evidence of chronic 
pancreatitis, and Cocker Spaniels had evidence for both acute and chronic pancreatitis (Watson 
et al., 2007). Miniature Schnauzers and Yorkshire Terriers have been reported to be over-
represented for pancreatitis in other studies (Schaer 1979; Cook et al., 1993; Hess et al., 1999; 
Steiner JM et al., 2010).  In one of these studies involving 70 dogs (Hess et al., 1999), the odds 
ratio for Yorkshire Terriers developing fatal acute pancreatitis was calculated to be 41.8 (95% 
CI: 1.0-1731). However, there appears to be conflicting evidence for breed susceptibility in the 
available literature; these same authors (Hess et al., 1999), considered the Miniature Poodle to 
be at decreased risk for fatal acute pancreatitis yet another study including 101 dogs identified 
this breed at increased risk for pancreatitis (Cook et al., 1993). Such differences in the 
veterinary literature may reflect other factors such as the genetic composition and breed 
frequencies of the populations under study, rather than true variations in susceptibility. 
However, not all dogs in the study conducted by Cook et al. were confirmed pancreatitis and 
some dogs were included on the basis of clinical signs and elevations in amylase and lipase 
activities alone. Conversely, all dogs in the study by Hess et al. were confirmed pancreatitis. 
However, all the dogs in this study had fatal pancreatitis. It is difficult to compare these two 
studies on the basis of the disparity between severity of disease in each population and for 
possible misallocation of dogs into the pancreatitis group in the Cook et al. study. 
 
Despite the evidence that some breeds may be at increased risk of developing acute 
pancreatitis, hereditary predisposition has not been proven conclusively. Pancreatic secretory 
trypsin inhibitor (PSTI) is a protective protein encoded by the SPINK1 gene that serves to 
protect against premature activation of trypsinogen within the pancreas (Bishop et al., 2010). In 
a study (Bishop et al., 2010) comprising sixty-four Miniature Schnauzers (39 with a history of 
pancreatitis and 25 without), the SPINK1 gene was sequenced in each dog and three variants 
were detected in each group.  Those with a history of pancreatitis were 9.5 times more likely to 
have at least a single copy of the three variant alleles compared to the healthy group. Further, 
the proportion of dogs with homozygous alleles for these variants compared with dogs 
heterozygous or having wild-type alleles, yielded an odds ratio (OR) for pancreatitis in the 
homozygous group of 3.4. The authors concluded that the variants in the SPINK1 gene likely 
played a role in the development of pancreatitis in Miniature Schnauzers but conceded that 
other genetic and environmental factors may also contribute (Bishop et al., 2010). 
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A subsequent study investigating heritability in Miniature Schnauzers found no relationship 
between variations in the SPINK1 gene and pancreatitis (Furrow et al., 2012). This case control 
study assessed 17 Miniature Schnauzers with pancreatitis and 60 Miniature Schnauzers with no 
significant gastrointestinal history. Further, the control dogs were older in this study compared to 
the study performed by Bishop et al. and therefore more representative of the population of 
dogs that are likely to be diagnosed with pancreatitis. 
 
Another study investigating a genetic relationship with canine pancreatitis focussed on the cystic 
fibrosis transmembrane conductance regulator (CFTR) gene (Spadafora et al., 2010). Atypical 
CFTR mutations are associated with pancreatitis in humans. This study screened for canine 
CFTR in 400 dogs. The study included 203 dogs with pancreatitis and 174 control dogs that 
were unwell for various reasons. Twenty-eight dogs were identified with one of four CFTR 
missense mutations. No relationship was identified between dogs with pancreatitis and control 
dogs. 
 
Age has also been suggested as a risk factor for acute pancreatitis; middle aged to older dogs 
have been identified at increased risk in some retrospective studies (Cook et al., 1993; Hess et 
al., 1999).  Hess et al., (1999) reported pancreatitis was more likely to develop in older dogs 
than in dogs less the one year of age, with an odds ratio of 27.5 (95% CI: 3.5-219) for dogs 5 to 
9 years old, and 36.9 (95% CI: 4.4-307) for dogs 10 years or older, and Cook et al., (1993) 
reported pancreatitis was more likely in dogs older than 7 years.   
 
One investigation into sex predilection for the development of pancreatitis reported that 
neutered males, sexually intact males and neutered females were more at risk of fatal acute 
pancreatitis than sexually intact females with odds ratios of 7.9 (95% CI: 0.5-128.6), 11.3 (95% 
CI: 0.9-140.4), and 22.0 (95% CI: 1.8-272.4) respectively, when adjusted for age (Hess et al., 
1999). In contrast, the study by Cook et al., (1993) involved a larger sample size and reported 
neutered males, females, and sexually intact females were at greater risk of pancreatitis than 
sexually intact males with odds ratios of 2.54 (95% CI: 0.97-6.65), 2.30 (95% CI: 0.75-7.08), and 
2.31 (95% CI: 1.09-4.89), respectively.   
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There have been many reports linking dietary indiscretion to pancreatitis in dogs. In one recent 
retrospective study, 198 dogs with a clinical diagnosis of pancreatitis (and 187 control dogs with 
a diagnosis of renal failure) demonstrated that ingestion of unusual food, such as table food or 
food different from the dog’s usual diet, increased the risk for developing pancreatitis (OR: 4.3 
95% CI: 1.7-10.7). This risk increased even further to 13.2 (95% CI: > 2.1) if the dog had access 
to “garbage” (Lem et al., 2008).  
 
The ingestion of a meal with a high fat content may precede canine acute pancreatitis and 
lipaemia may be present at the time of diagnosis (Cook et al., 1999; Hess et al., 1999). In some 
studies it has been shown that pancreatitis is more likely to develop in obese dogs after feeding 
high-fat diets or when they have high serum triglyceride concentrations, and has an increased 
severity when induced in dogs being fed a high-fat diet (Lindsay et al., 1948; Goodhead 1971; 
Hess et al., 1999; Xenoulis et al., 2010). Obesity may be more prevalent in older dogs and 
therefore may be a confounding factor (Mason 1970).  
 
Severe hypertriglyceridaemia is an established risk factor for pancreatitis in people (Cameron et 
al., 1974; Toskes 1990; Linares et al., 2008). Serum triglycerides may be hydrolysed by 
pancreatic lipase, producing excessive amounts of free fatty acids, which are toxic to the 
pancreas (Havel 1969; Saharia et al., 1977; Xenoulis et al., 2010). An alternate theory is 
hyperviscosity in the capillaries of the pancreas secondary to elevated concentrations of 
chylomicrons (Tsuang et al., 2009). These theories have been called into question because 
although there is a recognised threshold blood concentration of triglycerides which will 
predispose to pancreatitis in humans, there is no correlation above that threshold with severity 
(Talukdar et al., 2009). 
 
In an experimental model using isolated perfused canine pancreata, increased concentration of 
triglycerides induced pancreatic injury (Saharia et al., 1977). Despite this, hypertriglyceridaemia 
is not conclusively a cause of pancreatitis in dogs and may be simply a secondary effect of the 
pancreatitis itself. Recently (Xenoulis et al., 2011), triglyceride concentrations in 17 Miniature 
Schnauzers with a history of pancreatitis and 34 age-matched controls (also Miniature 
Schnauzers) without a history of pancreatitis were compared. Hypertriglyceridaemia was 
documented, even during quiescent periods, for the dogs with a history of pancreatitis, with an 
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odds ratio of 5.02 compared to the controls. The study concluded that further investigation was 
required to clarify the role of hypertriglyceridaemia as a predisposing factor of acute canine 
pancreatitis (Xenoulis et al., 2011).  
 
Concurrent disease is a common finding in cases of canine acute pancreatitis but it is difficult to 
determine if this is a significant and specific risk factor, since many diseases such as 
endocrinopathies, renal disease and neoplasia are more common in older dogs.  Diabetes 
mellitus, hyperadrenocorticism, and hypothyroidism have been reported as risk factors for 
pancreatitis in two studies with a combined total of 171 dogs (Cook et al., 1993, Hess et al., 
1999).  It is plausible that disorders of fat metabolism that predispose to hypertriglyceridaemia 
may also result in the development of pancreatitis. However, these associations have been 
described as weak at best (Steiner 2010).   
 
Certain drugs and medications have been implicated in canine pancreatitis, but a direct causal 
link is usually lacking.  Reports of some drugs inducing pancreatitis in people appear to have 
been adopted into the veterinary literature, not always with sufficiently robust evidence. Drugs 
commonly cited in both people and dogs as potentially causing pancreatitis include 
organophosphates, clomipramine, L-asparaginase, azathioprine, thiazides, frusemide, 
oestrogens, sulpha drugs, tetracycline, procainamide, and propofol (Frick et al., 1987; Teske et 
al., 1990; Lankisch et al., 1995; Trepanier 2004, Watson 2004; Steiner et al., 2008; Kook et al., 
2009; Steiner 2010, Schleis et al., 2011). In the veterinary literature, specific investigation of this 
association has been limited to azathioprine, potassium bromide, phenobarbital, and 
corticosteroids (Broe et al., 1983; Moriello et al., 1987; Housten et al., 1991; Gaskill et al., 2000; 
Steiner et al., 2008). Prednisone and dexamethasone have been investigated as a cause of 
canine pancreatitis but no evidence has supported this hypothesis (Parent 1982; Fittschen et 
al., 1984; Steiner et al., 2009). Elevated canine pancreatic lipase immunoreactivity 
concentrations were recorded in dogs receiving either potassium bromide, phenobarbitone, or a 
combination of the two drugs; however the authors were unable to establish a direct link with 
pancreatitis (Steiner et al., 2008). Azathioprine has also been implicated in case reports of dogs 
undergoing immunosuppression, but many of these dogs were concurrently receiving 
prednisolone, thus confounding any robust conclusions (Houston et al., 1991; Moriello et al., 
1987). Furthermore, a definitive confirmation of pancreatitis was lacking in both of these reports. 
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To investigate this further an isolated ex-vivo canine pancreas model was used to study the 
effect of azathioprine on the secretory functions of the pancreas (Broe et al., 1983). These 
authors demonstrated a significant increase in the secretory volume and bicarbonate output, 
and a profound decrease in trypsin output in azathioprine-perfused pancreata but there was no 
change in the appearance or weight compared to controls. They concluded that azathioprine 
had a marked effect on pancreatic function but did not elaborate further. 
 
Pancreatitis has also been linked to hypercalcaemia, after a dog with idiopathic hypocalcaemia 
that was supplemented with calcium developed the disease (Neuman, 1975). Zinc-induced 
pancreatic lesions appear to be well documented in many species, including the dog (Charles 
2007), and pancreatitis has been associated with zinc toxicosis in a Beagle, but this dog was 
also receiving potassium bromide for seizures, thus complicating the determination of causality 
(Mikszewski et al., 2003).  
 
Pancreatitis secondary to pancreatic duct obstruction may be due to neoplasia, chronic 
inflammation and fibrosis, as well as luminal occlusion of the pancreatic or common bile duct by 
parasites, inflammatory exudate, scar tissue, and pancreatoliths (Charles 2007). The majority of 
non-alcoholism-associated cases of human pancreatitis are attributed to gallstone obstruction of 
the bile or pancreatic ducts leading to increased intra-ductal pressure and subsequent 
premature activation of pancreatic enzymes (Cappell 2008). One study evaluating risk factors 
for pancreatitis concluded that obstruction of the pancreatic duct was the most likely inciting 
cause in two dogs with pancreatic neoplasia (Cook et al., 1993). However, conclusive cases of 
acute pancreatitis caused by naturally-occurring partial or complete obstruction of the pancreatic 
duct have not been reported. A study of surgical ligation of the bile duct in eight dogs that were 
subsequently necropsied at 8 weeks (4 dogs) and at 20 weeks (4 dogs) revealed fibrosis and 
atrophy of the pancreas, but no evidence of pancreatitis (Simpson et al.,1989). 
 
Duodenal reflux into the pancreatic duct occurs in normal dogs within 1 to 2 hours of feeding 
(Hendricks et al., 1980) and it has been suggested that in some dogs this backflow of activated 
pancreatic enzymes and bile salts may cause ductal necrosis, predisposing to the development 
of acute pancreatitis (Williams 1996; Watson 2004).  
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Finally, ischaemia and reperfusion have been demonstrated to cause pancreatitis in 
experimental models (Broe et al., 1982; Sanfey et al., 1985), and a meta-analysis of the human 
medical literature from 1966-2005 (Cuthbertson et al., 2006) revealed evidence that 
disturbances of both systemic and pancreatic microvasculature contribute to the development of 
pancreatitis. Similar studies have not been undertaken in dogs. Postoperative pancreatitis has 
also been reported in people with direct trauma, embolisation, and hypotension (White et al., 
1970). Trauma associated with biopsy of the pancreas has also been a concern for triggering 
pancreatitis in dogs. However, in a small study including four healthy Beagles, biopsy of the 
pancreas in three individuals combined with careful tissue handling was shown to be safe, with 
no changes in clinical health in the dogs during or after the procedure (Harmoinen et al., 2002).   
2.4 Pathogenesis 
 
Although the cause(s) of acute canine pancreatitis remain uncertain (see 2.3 above) it is 
generally accepted that pancreatitis develops as a result of autodigestion consequent to the 
premature activation of enzymes within the pancreatic acinar cells, irrespective of inciting cause 
(Simpson 1993).  
 
Pancreatic enzymes are secreted via exocytosis from the apices of acinar cells, as inactivated 
zymogen granules, into the pancreatic ducts (Ganong 2005, Mix et al., 2006). The zymogen 
trypsinogen is activated by enzymatic cleavage of trypsin activation peptide (TAP) from the 
amino terminal of the polypeptide chain. Enteropeptidase, an enzyme produced by enterocytes, 
is responsible for this cleavage, therefore, the process usually occurs once trypsinogen reaches 
the small intestinal lumen (Ganong 2005; Mix et al., 2006). Once cleaved, trypsin is able to 
convert other pro-enzymes, including trypsinogen, starting an autocatalytic chain reaction 
(Ganong 2005; Mix et al., 2006). However, other enzymes from a variety of sources, such as 
lysosomal proteases, are also able to activate zymogens. Abnormal fusion of lysosomes and 
zymogen granules in the acinar cells form giant cytoplasmic vacuoles (Saluja et al., 1987; 
Saluja et al., 1989; Steer 1992) and subsequent exposure of zymogen granules to an acidic 
environment in these giant vacuoles causes lysosomal hydrolysis and conversion to active 
enzymes, initiating pancreatic injury. This culminates in acute pancreatitis as evidenced by 
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inflammatory infiltrates, pancreatic oedema and haemorrhage, pancreatic necrosis and 
peripancreatic necrosis (Steer 1992; Simpson 1993).  
 
Protective mechanisms exist to prevent premature activation of trypsinogen to trypsin. These 
include: the synthesis of trypsin as the inactive pro-enzyme trypsinogen; rapid autolysis of 
activated trypsin; compartmentalization of activating enzymes in intracellular lysosomes; the 
production of counter-regulatory proteins, such as pancreatic secretory trypsin inhibitor (PSTI), 
by acinar cells (Simpson 1993); and a low intracellular ionised calcium concentration in acinar 
cells (Frossard et al., 2008; Petersen et al., 2011). If premature activation of trypsinogen occurs, 
PSTI, which is secreted simultaneously with trypsinogen, blocks the cascade of enzyme 
activation (Simpson 1993). Further, normal pancreatic secretions move along the pancreatic 
duct with unidirectional flow, minimizing reflux events. Pancreatic injury occurs once these 
protective mechanisms are exhausted and the digestive enzymes are prematurely activated.  
 
It is recognised that pancreatitis can progress to multiple organ dysfunction (Ruaux 2000). The 
release of cytokines initiates the systemic inflammatory response syndrome (SIRS), multiple 
organ dysfunction syndrome (MODS) and death (Ruaux 2000). In monitoring the progression of 
these syndromes in critically ill human patients with pancreatitis, the sequential organ failure 
assessment (SOFA) score and other clinicopathological indicators of MODS are useful 
prognostic indicators (Marshall et al., 1995; Vincent et al., 1998; Frossard et al., 2008). 
 
Abnormalities of a patient’s coagulation status are not specific for pancreatitis, but may be 
indicative of its severity. For example, Hess et al (1998) demonstrated that the activated partial 
thromboplastin time (aPTT) was prolonged in 61% (17/28) and prothrombin time (PT) was 
prolonged in 43% (12/28) of dogs with fatal acute pancreatitis. Of the 20 dogs with 
thrombocytopenia in this study, 55% (11/20) had prolonged aPTT or PT, but no relationship was 
found between platelet counts and aPTT or PT (Hess et al., 1998). In the same study, 16% 
(4/25) of dogs had an increased concentration of fibrin-split products. All four of these dogs had 
thrombocytopenia, but only 3 had either a prolonged aPTT or PT. In a more recent study of 61 
dogs with pancreatitis, haematopoietic complications such as thromboembolic events were not 
correlated with survival (Mansfield et al., 2008). Only 7 dogs in this study showed evidence of 
coagulation abnormalities, with 5 recovering to discharge. Although the measurement of these 
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parameters was recommended by Hess et al., (1998) these latter authors remained circumspect 
about their usefulness. 
 
2.5 The Diagnosis of Canine Pancreatitis 
 
 2.5.1  Introduction 
The diagnosis of canine pancreatitis can be challenging and is influenced by many patient and 
non-patient factors. As stated previously (and described below, in 2.5.3), the clinical signs are 
variable and non-specific (Cook et al., 1993; Hess at al., 1999)
 
and are shared with other 
diseases such as septic peritonitis or intestinal obstruction. The ability of the veterinarian to 
make a correct diagnosis of pancreatitis is paramount so that timely interventional treatment can 
be implemented. The implications of misdiagnosis in cases of acute abdomen may contribute to 
mortality. Thus, point-of-care testing may expedite the diagnostic process leading to more 
favourable outcomes. 
 
The use of history and physical examination, the application of diagnostic imaging modalities 
(radiology, ultrasound and computerised tomography), measurement of analytes (e.g. serum 
amylase and lipase activities), and, most recently, the evaluation of enzyme immunoassays that 
measure canine pancreatic lipase are the cornerstones of investigation for canine pancreatitis.  
These diagnostic tools will be reviewed in the following pages. 
 
There have been some diagnostic tests that, despite initially showing promise, have not gained 
acceptance for the diagnosis of pancreatitis. These include tests for trypsin-like 
immunoreactivity (TLI), trypsin activation peptide (TAP), trypsin alpha-1 proteinase inhibitor and 
alpha-2 macroglobulins (Ruaux et al., 1999; Mansfield et al., 2000; Suchodolski et al., 2001; 
Mansfield et al., 2003; Steiner et al., 2008). These tests are no longer available to veterinarians 
and will not be discussed further here. 
 
Any discussion regarding the accuracy of diagnostic testing procedures requires reference to a 
procedure that is often referred to as the ‘gold standard’ against which the sensitivity and 
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specificity is evaluated. For pancreatitis this alone is not without controversy and this section 
starts with a review of the value of pancreatic histopathology. 
 
2.5.2 The ‘Gold Standard’ of Diagnosis: Pancreatic Histology 
The term ‘gold standard’ is defined as “any standardised clinical assessment, method, 
procedure, intervention or measurement of known validity and reliability which is generally taken 
to be the best available, against which new tests or results and protocols are compared” (Segen 
1992).  In canine pancreatitis, pancreatic histology has been generally accepted as the gold 
standard for many years; however concerns regarding this parameter have been raised 
recently.  It has been suggested that this diagnostic test has its limitations regarding sensitivity 
since the parameters defining an acceptable level of canine pancreatic inflammation, as 
determined by histology, have been questioned (Mansfield et al., 2012). 
 
The accepted histological definition of acute pancreatitis in people is “an acute inflammatory 
process of the pancreas with variable involvement of other regional tissues or remote organ 
systems that does not lead to permanent changes” (Bradley 1993). In the dog, histologic 
characteristics that define acute pancreatitis are marked by neutrophilic inflammation with an 
absence of fibrosis or exocrine atrophy (Neuman et al., 2006). This neutrophilic inflammation is 
usually present within the parenchyma of the pancreas, peripancreatic fat, or both (Neuman et 
al., 2006). 
 
The inflammatory process can be restricted to small focal areas of inflammation and necrosis 
within the pancreas, or can extend over larger areas (Neuman et al., 2006), and herein lies the 
concern about the potential limitation of biopsy-derived histopathology as a tool for ante-mortem 
diagnosis. In a seminal post-mortem study by Newman et al (2004), pancreata were collected 
from 74 dogs consecutively presented for post mortem but without reported diagnosis. The 
pancreata were sectioned every 2cm from the tip of the right limb. Of the 47 dogs in the study 
with microscopic evidence of pancreatitis, very few had diffuse disease. In fact, less than one 
quarter of all sections from individual dogs displayed histological evidence of pancreatic 
inflammation and no single area of the pancreas could be recommended as a biopsy site, given 
that the location of inflammation varied (Newman et al., 2004). In addition, the gross 
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macroscopic appearance of the pancreas cannot be used reliably as a means of identifying an 
affected area to biopsy, given that only 5.5% of these dogs had gross changes yet 64% had 
microscopic evidence of disease. However, of those with macroscopic evidence of pancreatitis, 
this area was a productive biopsy site in all dogs tested (n= 4).  Therefore, the use of a single 
biopsy of the pancreas as a means of diagnosing acute pancreatitis, either via exploratory 
laparotomy or ultrasound-guidance, appears to be insensitive. Only dogs with gross lesions 
visible macroscopically, or by ultrasonographic imaging, could be expected to produce a 
diagnostic biopsy, and without this a large number of false negatives would be expected 
(Newman et al., 2006). In order to reliably diagnose pancreatitis histologically, a post-mortem 
would be required, with the pancreas transversely sectioned every 2 cm (Newman et al., 2006).  
This is obviously not applicable in the clinical practice setting. 
 
In a follow-up study to the one described above, histological assessment and grading of the 
pancreas was the focus of a 2006 paper by the same researchers (Newman et al, 2006), with 
the stated aim to advance the classification of pancreatic disease. A standardised grading 
system was proposed for canine pancreatic inflammatory disease after examination of 101 
pancreata collected within 6 hours of death from dogs presenting for necropsy to a referral 
hospital. The grades included not only the presence of neutrophilic inflammation, lymphocytic 
inflammation and necrosis mentioned above, but also pancreatic fat necrosis, oedema, fibrosis, 
atrophy and hyperplastic nodules. In this study, tissue sections were obtained every 2cm from 
the tip of the right limb of the pancreas. Historical information was compatible with pancreatitis 
in some of these dogs. Grades were allocated as 0 for the absence of lesions or 1, 2, or 3 
based on increasing severity for each section. Scores of 1, 2, or 3 were defined as; less than 
10% of the section affected, 10 – 40% affected, or greater than 40% affected, respectively. A 
mean cumulative score (MCS) was then determined by summating the score of single sections 
and dividing this by the number of sections evaluated for that pancreas. An MCS > 0.0 but ≤ 1.0 
was considered mild, >1.0 but ≤ 2.0 considered moderate, and > 2.0 was considered severe. 
Pancreatic lesions were identified in 92% of all dogs in this study using this system of grading. 
Pancreatic nodules followed by lymphocytic inflammation, fibrosis and atrophy were the most 
common lesions, followed then by neutrophilic inflammation, pancreatic fat necrosis, pancreatic 
necrosis and, finally, oedema. This grading system has been adopted by three of four recent 
studies evaluating the sensitivity and specificity of canine pancreatic lipase (Steiner et al., 2008; 
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Neilsen-Carley et al., 2011; Trivedi et al., 2011), although Neilsen-Carley et al (2011) were the 
only authors to use pancreatic nodules as an inclusion criteria.  
 
Recently, Mansfield et al. (2012) suggested that this approach may present limitations, as a 
lesion in any pancreatic section automatically constituted mild pancreatic disease, yet this may 
simply represent normal variation. The histological grading system used for Mansfield et al.’s 
study was adapted from two previous studies (Newman et al., 2006; Watson et al., 2007). This 
approach allows for a score of 0 for absence of inflammation or if less than two small foci of 
mononuclear cells were present with no disruption to the architecture in any of three sections 
from the left, right, and body of the pancreas (Mansfield et al., 2012). Scores of 0 to 4 are added 
from the three sections to provide a total score out of 12.  A score of 1 indicated less than 5% 
neutrophilic or lymphoplasmacytic inflammation; 2 indicated 5 to 50% neutrophilic or 
lymphoplasmacytic inflammation; 3 indicated > 50% neutrophilic or lymphoplasmacytic 
inflammation; and 4 indicated necrosis of pancreatic tissue or peripancreatic necrosis / steatitis. 
 
In summary, this latest grading system signals a movement away from the stringent nature of 
the previous system to allow for some lesions to be present without having to classify the 
pancreas as mildly affected, yet retains pancreatic histopathology as the gold standard against 
which all other testing procedures can be evaluated. Furthermore, the focus in this grading 
system is on inflammation rather than oedema, nodules, atrophy and fibrosis.   
 
 2.5.3  Patient Anamnesis 
Pancreatitis in dogs can present with a nebulous history. In a report examining 70 cases of fatal 
acute pancreatitis, 91% of dogs had a history of anorexia, 90% had a history of vomiting, 79% 
weakness, 50% polyuria and polydipsia, 33% diarrhoea, 20% neurologic abnormalities, 16% 
melaena, 11% seizures, 10% haematemesis, and 4% haematochezia (Hess et al., 1998). This 
study is skewed towards the more severe cases, as these are more likely to be fatal, and 
therefore likely to have more severe signs in their history. Another more recent report supports 
these findings (Pápa et al., 2011). It is generally accepted that while certain clinical signs, as 
reported in the history, are consistent with a diagnosis of pancreatitis, none if these are specific 
and, therefore, patient anamnesis alone is non-diagnostic. 
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2.5.4 Physical Examination 
The physical examination findings in dogs with pancreatitis are non-specific and similar to that 
found in animals with other causes of abdominal disease. Physical examination abnormalities at 
the time of presentation include abdominal pain, moderate to severe dehydration, obesity, 
pyrexia, and icterus (Hess et al., 1998; Pápa et al., 2011). 
 
2.5.5 Diagnostic Imaging 
2.5.5.1 Radiography 
Abdominal radiography plays an important role in determining the underlying causes of the 
canine acute abdomen. However, its usefulness in discerning pancreatitis from other causes is 
somewhat limited. Abdominal radiographs were assessed in 209 dogs determined (by the 
standards of the day) to have pancreatitis in a retrospective study gathering cases from 1967 to 
1976 (Kleine et al., 1978). Of these dogs, 17 had biopsy-proven pancreatitis, 72 were proven by 
necropsy, and 120 displayed abdominal pain, fever, a serum amylase level of at least twice the 
reference range, with the authors reporting the exclusion of other causes of elevated amylase. 
Of these, 182 dogs had technically satisfactory radiographs and were included in further 
analyses.  
 
The most common abnormality identified was increased density, diminished contrast, and 
granularity in the right cranial abdomen in 58% of dogs (106/182). The stomach was displaced 
toward the left side or the pyloric antral border was truncated in 55% of dogs (100/182). A mass-
effect medial to the proximal descending duodenum or duodenal displacement toward the right 
side was observed in 42% (77/182) dogs. A gas pattern within, or thickened walls of, the 
descending duodenum were noted in 23% (42/182) of dogs and finally, a gas pattern in, or 
caudal displacement of, the transverse colon was noted in 9% (17/182) of dogs (Kleine et al., 
1978). The authors concluded that radiography is an important adjunct in the diagnosis of 
pancreatitis as it may arouse suspicion of acute pancreatitis while allowing for investigation of 
other disorders that present as acute abdominal disease. Many of these disorders require 
emergency surgical intervention and may be detected by radiography. Also, radiographic 
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evidence may guide the clinician away from the potentially harmful effects of surgery in dogs 
with acute pancreatitis (Kleine et al., 1978). 
 
In a retrospective study of 70 fatal cases of acute pancreatitis, 41 dogs had abdominal 
radiographs available for review (Hess et al., 1998). A single board certified veterinary 
radiologist determined that only 24% (10/41) had abnormalities suggestive of acute pancreatitis, 
concluding that conventional radiography is an insensitive test for the diagnosis of pancreatitis. 
 
2.5.5.2 Abdominal Ultrasonography 
Ultrasonographic techniques and equipment have improved considerably over the last 30 years. 
The development of ultrasonographic technique to establish the presence or absence of 
pancreatic disease has relied on establishment of normal landmarks in conjunction with 
experimentally induced and naturally occurring lesions. Early studies focussed on the ability to 
detect the pancreas in the first place, together with descriptions of sonographic changes that 
were deemed to occur during pancreatitis, and later studies have evaluated the accuracy of 
such testing.    
 
Ultrasonographic features of experimentally-induced acute pancreatitis in three dogs were 
described in 1983 (Nyland et al., 1983). Pancreatitis was induced by oleic acid infused directly 
into the pancreas and twice daily ultrasound examinations were performed for 5 days until 
euthanasia. In-homogenous masses were noted in the right pancreatic lobe, with increased 
density of the left pancreatic lobe. At this early point in the development of veterinary 
ultrasonography, the authors stressed that the normal canine pancreas could not be accurately 
delineated by this modality. They were cautious about drawing conclusions between the image 
characteristics of experimentally induced pancreatitis and naturally occurring pancreatitis 
(Nyland et al., 1983).  A similar experimental study a few years later (Murtaugh et al., 1985) also 
noted difficulty in obtaining a clear image of the normal pancreas, which was likely due to the 
equipment limitations of the time. However, identification of ill-defined masses with in-
homogeneous echogenicity accompanying an overall decrease in echogenicity was detected in 
the right and left lobes once pancreatitis had developed. The pancreata were imaged by 
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ultrasonography ex vivo during post mortem to confirm the echotexture observed during the 
experiment.  
 
In a study by Lamb et al. (1995), four dogs were administered IV cholecystokinin to induce 
pancreatitis and compared with four control dogs given IV saline. Ultrasonography of the 
pancreas was performed at 0, 2, 4, and 6 hours after the infusion. Immediately after the final 
ultrasound the dogs were euthanized and the pancreas was removed for histological 
examination. Rapid onset of pancreatitis was noted in all 4 dogs given cholecystokinin and 
confirmed by histology. Heterogeneous hypoechoic lesions and oedema were detected by 
ultrasound at either 2 or 4 hours after the start of infusion, and the authors describe ‘tiger stripe’ 
interlobular oedema to be characteristic of the cholecystokinin-induced pancreatitis. There were 
no significant changes in the control dogs.  More recent ultrasonographic abnormalities of acute 
pancreatitis were described as a hypoechoic pancreas and hyperechoic peripancreatic 
mesentery (Saunders 1991).  
 
The landmark study of fatal acute pancreatitis which included abdominal ultrasound evaluations 
was published in 1998 (Hess et al., 1998). These authors gathered retrospective data from dogs 
with pancreatitis between 1986 and 1995. Of the 70 cases of fatal acute pancreatitis, as 
confirmed by necropsy, 34 dogs had abdominal ultrasound examinations. Of these, 68% (23/34) 
had sonographic evidence suggestive of acute pancreatitis, as defined by Saunders (1991). 
Later, in another retrospective study (Hess et al., 2000) evaluating concurrent disorders in 
canine diabetes, four dogs with histopathology of the pancreas consistent with pancreatitis also 
had abdominal ultrasound abnormalities consistent with pancreatitis. The ultrasound images 
were interpreted by the same radiologist interpreting the images from the previously described 
study. 
 
These results have been further supported by the two most recent studies (Steiner et al., 2008; 
Trivedi et al., 2011), which confirm the usefulness of ultrasonography as a diagnostic modality 
for pancreatitis. In 22 dogs with confirmed pancreatitis by histopathology, nine underwent 
abdominal ultrasonography prior to euthanasia. These 22 dogs were selected for examination 
due to macroscopic evidence of pancreatitis from a group of 208 dogs presented for necropsy. 
Of the 22 dogs, 20 had at least one of the following clinical signs reported prior to euthanasia; 
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vomiting, anorexia, abdominal pain, or diarrhoea. The reason for presentation was never 
reported for these dogs (Steiner et al., 2008). Of these, 66% (6/9) displayed sonographic 
changes consistent with pancreatitis. The severity of their pancreatitis was assessed 
histologically by grading the percentage of sections affected. Virtually all of the dogs in this 
study had very mild pancreatitis as assessed by histopathology, yet histological severity of 
pancreatitis was increased in the dogs with ultrasonographic evidence of pancreatitis. The most 
recent study by Trivedi et al., (2011) reported that 100% (8/8) of dogs with histologically 
confirmed pancreatitis had ultrasonographic changes consistent with pancreatitis. Interestingly, 
the Spec cPL® result was lower than 400μg/L in 50% (4/8) of these dogs, suggesting an 
increased sensitivity of ultrasound examination compared with this enzyme immunoassay (see 
section 2.5.7.4). 
 
2.5.5.3 Computed Tomography 
A case report of two dogs (Jaeger et al., 2003) introduced the use of computed tomography 
(CT) for assistance in the diagnosis of acute necrotizing pancreatitis. In one dog, the left 
pancreatic lobe formed an irregular mass that was hypoattenuating relative to the spleen. 
Images obtained after iodinated contrast administration showed the central portion of the 
pancreas greatly enhanced, surrounded by non-enhancing, hypo-attenuated peripheral tissue, 
which was interpreted as necrosis of the pancreas. The pancreas was also enlarged. A 
limitation of this report is the absence of confirmed diagnosis by histopathology or post mortem. 
Cytological evaluation of the pancreas in one case was consistent with pancreatic necrosis 
although the sensitivity of this method to establish a diagnosis of pancreatitis is unknown. In the 
second dog, the pancreas was enlarged and heterogeneous, and there was also thickened 
mesentery and free abdominal fluid. The right lobe and body of the pancreas were markedly 
enhanced after iodinated contrast, with the left limb non-enhancing, consistent with necrosis of 
the left limb of the pancreas. Similar to the first case, cytology of the pancreatic tissue was 
consistent with pancreatic necrosis. The advantages of CT also include the identification of 
vascular thrombosis, although colour doppler ultrasound has proven more sensitive in humans 
(Dorffel et al., 2000). 
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The disadvantages associated with using CT include general anaesthesia and the use of 
contrast material. Subsequent hypotension or disturbances in the microcirculation that may 
occur due to these drugs makes this procedure relatively contraindicated in dogs with 
pancreatitis. The use of helical CT by Jaeger et al., (2003) allowed for rapid acquisition of 
images and only required the use of short acting sedation. A combination of fentanyl, diazepam 
and ketamine for sedation successfully avoided hypotension that may be seen with inhalational 
anaesthetics. Regardless, the use of CT is also limited by its cost, access, and interpretation of 
images by qualified personnel. 
 
2.5.6 Clinical Pathology 
  2.5.6.1 Routine Clinical Pathology 
Routine complete blood count (CBC) collected from dogs with acute pancreatitis most often 
shows a leukocytosis. In the report by Hess et al., (1998), 62% of dogs (37/60) had a 
leukocytosis, with 84% (31/37) of these exhibiting a left shift. Only 3.3% (2/60) of dogs had a 
leukopaenia. Anaemia was reported in 8 of 63 dogs and five of these had a perceived 
inadequate reticulocyte response. Thrombocytopenia was observed in 59% (20/34) of dogs in 
the same study. In a study describing experimentally-induced pancreatitis, leukocytosis was 
demonstrated in each of six dogs, with neutrophil numbers peaking 2-3 days after pancreatic 
insult (Brobst et al., 1970).  
 
Serum biochemistry in the study by Hess et al., (1998) revealed elevated urea and creatinine in 
53% (33/62) and 59% (36/61) of dogs, respectively, that died due to fatal acute pancreatitis. 
Serum phosphate was also elevated in 68% (41/60) of their cases. There were also elevations 
in alanine aminotransferase (ALT) 61% (35/57) and alkaline phosphatase (ALP) 79% (46/58) 
activities, total bilirubin 53% (31/58), and cholesterol 48% (29/60). Serum albumin was low in 
50% (30/60) of dogs.   
Interestingly, despite 97% of dogs in the same study being assessed as either moderately or 
severely dehydrated, 90% (35/39) had either isothenuric or hyposthenuric urine. It is unknown if 
these dogs had received intravenous fluids prior to urinalysis and the reasons for this finding 
were not reported by the study. 
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Taken together, these results derived from a total of 70 dogs with fatal acute pancreatitis 
demonstrate that no single parameter within the framework of routine clinical pathology 
(haematology, serum biochemistry or urinalysis) is specific for the diagnosis of pancreatitis 
(serum amylase and lipase will be discussed in the next sections). They are, however, useful for 
assessing the current health status of the dog and may be indicative of existing co-morbidities, 
or guide further diagnostics after ruling out other possible differential diagnoses. 
 
  2.5.6.2 Serum Amylase Activity 
Amylase is an enzyme that catalyses the hydrolysis of starch into sugars. It is found in fluid from 
the exocrine pancreas, where it is synthesised and stored in acinar cells with pancreatic lipase. 
Both amylase and lipase form an important component of the digestive process.  Four isoforms 
of amylase have been identified in the dog (Murtaugh et al., 1985) and both have been studied 
extensively for its usefulness in the diagnosis of pancreatitis due the presumption that its serum 
activity would be elevated during pancreatic insult (Brobst et al., 1970; Mia et al., 1978; 
Strombeck et al., 1981; Simpson et al., 1989; Simpson et al., 1991; Hess etal., 1998; Mansfield 
et al., 2000; Steiner et al., 2008; Trivedi et al., 2011). An increased plasma level of amylase 
activity was therefore thought to be indicative of pancreatic inflammation, however this 
hypothesis has been investigated and challenged by many authors. 
 
Early studies revealed that pancreatectomy in dogs did not significantly reduce serum amylase 
activity, indicating that there are sources of amylase other than the pancreas (Simpson et al., 
1991). It was also recognised early that hyperamylasaemia may be present in dogs without 
pancreatitis, in animals with decreased renal function and with gastrointestinal and hepatobiliary 
diseases (Polzin et al., 1983; Strombeck et al., 1981).  
 
Brobst et al. (1970) used an experimental model to investigate amylase activity in pancreatitis.  
Pancreatitis was induced in dogs by either injecting carbon tetrachloride into the pancreatic 
parenchyma or by infusing chyme, trypsin, or a combination of these, in a retrograde direction 
from the duodenum into the pancreatic duct. Serum amylase activity was maximal 1-2 days 
after pancreatic insult in 100% (6/6) of dogs and values increased by a mean of 8 times 
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baseline values. Later, Mia et al. (1978) established a normal reference interval for serum 
amylase activity of 250-1500 Caraway units/dl, using 44 healthy dogs and the iodometric 
method. Pancreatitis was experimentally induced in these dogs and peak serum amylase 
activities were measured at between 4,500 to 14,000 Caraway units/dl. These studies illustrated 
that serum amylase elevations could be produced by  pancreatic injury. 
 
The pancreatic isoform of serum amylase was found to be elevated in canine pancreatitis 
compared to control dogs (Murtaugh et al., 1985). Measurement of the pancreatic isoform 
requires agarose-gel electrophoresis. Its measurement was thought to be of value in cases of 
suspected pancreatitis, to identify pancreatic acinar leakage when normoamylasaemia was 
present and potentially distinguish cases of extra-pancreatic hyperamylasaemia (Murtaugh et 
al., 1985). Measurement of this isoform of amylase however has not become routine practice, 
due in part to its complexity and cost. 
 
Reporting serum amylase activity for the diagnosis of pancreatitis has continued to this day, but 
largely in the context of comparing its usefulness (or otherwise) to the spectrum of diagnostic 
tests that are available today (Trivedi et al., 2011). In a large retrospective study, Strombeck et 
al. (1981) investigated the relationship between canine serum lipase and amylase activities in 
713 routine clinic cases where these values were measured together. A range of 0 to 100 U/L of 
lipase activity was used to classify dogs as not having pancreatitis (none of these had 
pancreatic lesions at necropsy). The authors reported normal mean serum amylase activity of 
2,980 U/L ± 1,490 (standard deviation, SD) with a range of serum amylase activity determined 
as 0 to 4,029 U/L. Serum lipase values of less than 800 U/L were measured in 567 dogs and 
only 0.82% of total variation in serum amylase could be explained by the corresponding lipase 
values (r = 0.09). The serum amylase activity was then correlated to paired serum lipase 
activities for values over 800 U/L (146 dogs) and 30.6% of the amylase activity variation could 
be explained by lipase in this group (r = 0.55). This was then compared to dogs with serum 
lipase concentrations of between 700-799 U/L as these were grouped as “probably having” 
pancreatitis. For this group, the mean serum amylase activity ± 2 SD ranged from 857 to 4,869 
U/L. The mean was not reported by the authors. The authors concluded that the range of 
amylase activities were essentially the same for dogs from both groups, and did not endorse its 
use for diagnosing pancreatitis.   
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Surgical ligation of the pancreatic duct in eight dogs was used to induce pancreatitis and 100% 
(8/8) of dogs showed increase amylase activity (Simpson et al., 1989). Baseline values for 
lipase activity ranged from 294 to 1,232 IU/L with a mean of 638 IU/L. Post-ligation lipase 
activities increased by 13.7 fold, with a range of 3,400 to 11,400 U/L. Amylase elevations 
persisted above the reference range for more than 14 days after surgery in only 2 of 8 dogs. As 
there have been no confirmed reports of naturally occurring pancreatic duct obstruction-induced 
pancreatitis in the dog (refer to earlier review), the use of this model to determine the clinical 
utility of serum amylase for the diagnosis of canine pancreatitis appears dubious, in retrospect.  
 
Serum amylase activity was measured in 39 dogs with naturally occurring fatal acute 
pancreatitis and 69% (27/39) of dogs had elevated concentrations (Hess et al., 1998). As with 
lipase, the authors concluded amylase to have limited diagnostic usefulness. Steiner et al. 
(2008) showed that in dogs with naturally occurring macroscopic evidence of pancreatitis, 
serum amylase concentrations were above the reference interval in 40.9% (9/22). When a value 
three times the reference limit was applied, the figure was reduced to 18.2% (4/22) of dogs.   
 
Amylase activity was measured in healthy dogs (n = 36), in dogs with renal disease (n = 7), in 
dogs with histologically confirmed pancreatitis (n=15), and in dogs with various other diseases 
(n= 26) in a retrospective study (Mansfield et al., 2000). The sensitivity and specificity of serum 
amylase was found to be 62.1% and 55%, respectively. The authors also demonstrated a 
concomitant elevation in lipase in 66.6% of dogs with pancreatitis. Despite this, it was concluded 
there was significant overlap between dogs with pancreatitis and those with other diseases, 
making the diagnostic utility alone or together with lipase unreliable (Mansfield et al., 2000). 
 
In the most recent report evaluating the value of enzyme activity for the diagnosis of 
pancreatitis, Trivedi et al., (2011) used 70 dogs with and without histological evidence of 
pancreatitis. Serum amylase was found to have a sensitivity and specificity of 14% and 100%, 
respectively, for moderate to severe pancreatitis using a cut-off value of 1,240 U/L. However, 
there were only seven dogs in this report without pancreatitis, making the strength of the 
specificity result questionable (Trivedi et al., 2011). Further, many of the dogs necropsied in this 
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study may have pancreatic inflammation secondary to other disease processes, as the primary 
diagnoses were not reported. 
 
2.5.6.3 Serum Lipase 
Lipases are water-soluble enzymes that hydrolyse lipids into polar lipolysis products (Svendsen 
1994) and are produced by many tissues, including the pancreas (Steiner et al., 2002). Serum 
lipase activity, as an indicator of pancreatic lipase activity, has been evaluated for decades in 
the diagnosis of canine pancreatitis (Brobst et al., 1970; Mia et al., 1978; Strombeck et al., 
1981; Simpson et al., 1989; Simpson et al., 1991; Hess et al., 1998; Mansfield et al., 2000; 
Steiner et al., 2008; Trivedi et al., 2011) but its use as a diagnostic tool has remained 
controversial. 
 
In people, there have been many sources and types of this enzyme identified, such as gastric 
lipase, hepatic lipase, lipoprotein lipase, hormone sensitive lipase, in addition to pancreatic 
lipase (Svendsen 1994).  Although lipases have limited amino acid homology they share a 
highly conserved sequence of 3 amino acids that serve as the catalytic triad, or hydrolysis 
mechanism, formed by serine, aspartic acid and histidine (Svendsen 1994). This makes 
catalytic assays vulnerable to measurement of lipases derived from sources other than the 
pancreas. In support of this notion, Simpson et al. (1991) found that serum lipase activities were 
not decreased in dogs that underwent pancreatectomy, indicating that, like in humans, there are 
other sources of lipase in the dog (Simpson et al., 1991). In addition, there were no differences 
in serum lipase concentrations between 75 healthy dogs and 25 dogs diagnosed with exocrine 
pancreatic insufficiency (Steiner et al., 2006).  
 
In the study of 6 dogs performed in 1970 by Brobst et al., referred to previously, lipase activity 
peaked 1-2 days after pancreatic insult in 83% (5/6) of dogs and values increased by a mean of 
57 times the baseline values. The remaining dog’s peak lipase value was found on day 8. The 
study further demonstrated that serum lipase activity closely paralleled serum amylase activity 
in 5 of 6 dogs in experimentally-induced pancreatitis. 
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In addition to measurement of serum amylase activity, the study by Mia et al. (1978) also 
evaluated normal serum lipase values in 44 healthy dogs and, also, elevations during 
experimentally induced pancreatitis in 8 dogs (Mia et al., 1978). Serum lipase activity in normal 
dogs was determined to be 0 to 50 IU/L and ranged from 325 to 810 IU/L post pancreatic injury. 
This study also showed parallel increases in amylase and lipase in 6 of 8 dogs, with serum 
amylase activities returning to normal earlier than that of serum lipase.  
 
At the time of the retrospective report published by Strombeck et al. 1981, which investigated 
the relationship between serum lipase and amylase values, canine serum lipase activity 
reference intervals were only tentatively established. Therefore the authors’ laboratory 
determined the mean activity of lipase in healthy dogs to be 150 U/L ± 125 U/L SD. In 713 
cases that were assessed from hospital records, serum lipase activity had a tenuous 
relationship with serum amylase activity when increased above 800 U/L. Above this level, the 
estimated correlation coefficient (r) between lipase and amylase was = 0.55 and approximately 
30% of the variation in the amylase values could be explained by changes in the lipase values 
(Strombeck et al., 1981). Necropsy findings were reported in 92 dogs. Serum lipase was greater 
than 800 U/L in 25 of these dogs, with pancreatic lesions in 19 and only 10 of these with 
evidence of pancreatitis. For lipase activities between 500 and 799 U/L in the necropsy group, 8 
of 14 had pancreatitis or pancreatic carcinoma. Of the 53 remaining dogs with lipase activities 
below 500 U/L only 1 had pancreatitis. The authors concluded that low serum lipase activity 
values almost always ruled out pancreatitis but that elevated levels of lipase were not 
pathognomonic for pancreatitis.  In fact, necropsy results illustrated that elevations in lipase 
were also associated with renal and hepatic disease in the absence of pancreatic involvement, 
analogous to serum amylase activity, which was most likely due to decreased clearance. 
 
Lipase activity was measured in a study of 8 dogs after pancreatic duct ligation (Simpson et al., 
1989). Baseline values ranged from 68 to 560 U/L with a mean of 265 U/L. Post ligation lipase 
values increased by a mean of 25.6 fold with a range of 4,500 to 13,600 U/L. Lipase elevations 
persisted for more than 14 days after surgery in 6 of 8 dogs. The authors of this study 
concluded that lipase activity was a more reliable indicator of pancreatitis than amylase activity 
due to higher peak increases in all dogs. The limitations of this study with reference to ductal 
ligation as a cause of pancreatitis in dogs have been discussed previously.  
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In a retrospective study of 70 histologically confirmed cases of fatal acute pancreatitis, only 39% 
(16/41) of dogs had elevated serum lipase activity. The authors also concluded that the 
sensitivity appeared to be poor (Hess et al., 1998). There were no values of lipase activity below 
the normal range in this study. 
 
Lipase activities were also evaluated in the retrospective study by Mansfield et al. (2000). The 
sensitivity of serum lipase was found to be 73% and specificity 55%. Many dogs without 
pancreatitis had elevations greater than fivefold. The authors concluded that there was 
significant overlap between dogs with pancreatitis and those with other diseases, but there was 
no guarantee that a dog with pancreatitis would have elevated lipase activity (Mansfield et al., 
2000). At about the same time, in a study reported only in conference proceedings (Steiner et 
al., 2001), lipase activity in 11 dogs with histologically-confirmed, naturally occurring pancreatitis 
was reported to be significantly higher than in a group of 74 healthy dogs, with mean ± SD 
lipase activity found to be 319 ± 146 U/L and 4512 ± 5375, respectively. However, only 7/11 
dogs had serum lipase activity above the reference interval and a cut-off using 3 times the 
reference range reduced this number to 6/11, producing a sensitivity of only 54.5%.  
 
A more recent study evaluating canine pancreata displaying macroscopic evidence of 
pancreatitis revealed that only 41% (9/22) of dogs had elevated ante-mortem lipase activities 
(Steiner et al., 2008). Macroscopic pancreatitis inclusion criteria included peripancreatic fat 
necrosis, pancreatic haemorrhage, presence of pus when the organ was cut, or a dull granular 
capsular surface in this study.  The authors suggested a cut-off value of 3 times the reference 
for serum lipase activity in order to exclude false positives that had been demonstrated in other 
studies. This reduced the sensitivity to 13.6% (3/22) however. One of the limitations of this study 
involved the nature of acquisition of the pancreata, which were obtained solely due to their 
gross evidence of pancreatitis from a larger necropsy group. The reasons for necropsy were not 
reported, and concurrent disease could not be ruled out.   
 
Trivedi et al., 2011 improved on the previous study by using dogs with histological evidence of 
pancreatitis to evaluate the diagnostic accuracy of serum lipase activity. Unfortunately, similar to 
the report by Steiner et al. (2008), this study also included necropsies of dogs where the 
reasons for presentation were not reported. Therefore, many cases were unlikely to have had 
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primary pancreatitis. The authors grouped dogs by severity of histological pancreatic lesions 
into mild and moderate-to-severe. The sensitivity and specificity of lipase activity was found to 
be 54% and 43% for the mild group and 71% and 43% for the moderate-to-severe group, 
respectively. 
Investigations examining lipase activity in various diseases other than pancreatitis have also 
been undertaken. Studies of serum lipase activity in dogs with chronic renal failure have 
reported contrasting results. One study by Polzin et al. (1983) found that an increase in lipase 
activity was associated with renal failure, whereas Steiner et al. (2010) found there was no 
significant difference in lipase activity in dogs with experimentally-induced chronic renal failure 
compared with a control population. In the more recent study of 16 dogs with chronic renal 
failure, experimentally induced by nephrectomy, serum lipase activity was within the reference 
range for all dogs, with a median value of 266.5 U/L versus the healthy control group of 74 dogs 
(294.5 U/L). Unfortunately, no pre-nephrectomy lipase activities were measured in this study as 
the serum was collected from dogs in an unrelated project 20 years earlier. 
 
The differences between the lipase assay results reported in these 2 studies could be explained 
by the differences in substrates used, as these studies are separated by greater than 20 years. 
The authors (Steiner at al., 2010) acknowledged that a particular lipase in the study performed 
in 1983 may have reacted with the test substrate of the time, yielding the elevations not seen 
with the current methodology. Only mild azotaemia was detected in many dogs in the more 
recent study, possibly indicating that lack of severity in renal dysfunction may have been 
responsible for the discord in results. However, there was no direct correlation detected in this 
study between creatinine concentration and serum lipase activity, which the authors used to 
refute this notion. Further, the stability of lipase stored at minus 80 degrees for 20 years is not 
known, which may also have affected the results. 
 
Elevations in serum lipase have also been demonstrated in dogs with gastritis, gastroenteritis, 
or duodenal foreign body. In a group of 48 young dogs, 16 with canine parvovirus enteritis and 
32 with enteritis or gastroenteritis having no definable underlying cause, 27.1% (13/48) had 
serum lipase activities above the laboratory reference range (Rallis et al., 1996). The authors 
were unable to rule out pancreatic involvement but concluded that hyperlipasaemia may also be 
attributed to “gastrointestinal disturbance”. Further, in a case report of two dogs with duodenal 
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foreign bodies, both had serum lipase activities greater than twice the reference range (Willard 
et al., 1993). One limitation of these studies is the possible decrease in glomerular filtration rate 
in affected dogs, leading to decreased lipase excretion. These studies do not adequately report 
renal function in these dogs and impaired function could have contributed to lipase elevations. 
Further, dehydration leading to decreased pancreatic perfusion and secondary pancreatic 
inflammation could contribute to increased serum lipase activity.  
 
Pancreatic and hepatic neoplasia was also proposed to have been responsible for increases in 
serum lipase activity, with minimal concurrent increase in serum amylase activity, in a small 
study of six dogs. Serum lipase activity ranged from 5410 U/L to 42,900 U/L, 11 to 93 times the 
upper reference limit. Histochemical and immunohistochemical staining patterns suggested 
tumour lipase production in 5 of the 6 dogs. The authors concluded that marked, unexplained 
hyperlipasaemia may be a non-invasive indicator for neoplasia of the pancreas and liver in dogs 
(Quigley et al., 2001). 
 
Anecdotally, corticosteroids have been mooted to cause pancreatitis. A prospective study 
evaluating the effect of dexamethasone on serum lipase demonstrated a significant increase in 
lipase activity in dogs treated with a high dose (2mg/kg) subcutaneously 3 times on day 8 (n=6), 
and with a low dose (0.2mg/kg) given subcutaneously 3 times a day (n=6) for 22 days, 
compared with control dogs (2 groups of n=6) that received the dexamethasone vehicle only 
(Parent 1982). Measurements were taken on days 3, 5, and 8 for all dogs and continued for 
days 12, 15, 19, and 22 in the low dose group. All dogs were necropsied after the conclusion of 
the injections and no evidence of pancreatitis was found. In another similar study, 30 dogs were 
divided into 5 groups of 6, with group 1 receiving no intervention, group 2 receiving 0.6mg/kg 
prednisone twice daily by mouth, group 3 receiving 2mg/kg prednisone twice daily by mouth, 
group 4 receiving the prednisone injectable vehicle to the same volume as group 5, which 
received 4mg/kg prednisone intramuscularly once a day (Fittschen et al.,1984). Serum lipase 
was measured on days 0, 6, 11 and 15. Only on day 6 in the intramuscular prednisone group 
(group 5) were serum lipase concentrations significantly increased above baseline.  
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All dogs were necropsied and no ultrastructural changes were observed in the pancreata of 
dogs receiving prednisone. One dog in group 5 had evidence of mild pancreatitis, as defined by 
a few foci of fat necrosis surrounded by sparse neutrophilic infiltrate (Fittschen et al., 1984). 
In the previously mentioned studies examining the effects of dexamethasone on serum lipase 
activity, serum amylase was also evaluated (Parent 1982, Fittschen et al., 1984). Both studies 
showed a significant decrease in serum amylase in treated dogs, compared to controls, on all 
days measured. 
 
Elevated serum lipase activity has also been linked with potassium bromide and phenobarbital 
therapy. Two separate retrospective studies in dogs showed increases in serum lipase activity 
with potassium bromide and phenobarbital therapy, separately and in combination (Gaskill et 
al., 2000, Steiner et al., 2008). The presence or absence of pancreatic inflammation could not 
be demonstrated, as pancreatic histology was performed in very few dogs.  
 
2.5.7 Enzyme-linked Immunosorbent Assay (ELISA) for the 
Diagnosis of Pancreatitis 
2.5.7.1 Principles 
 
The ELISA is a form of enzyme immunoassay that utilises antibodies as reagents to identify 
antigens (e.g. canine pancreatic lipase) in order to allow quantification (Crowther 2001). The 
methodology of interest in this thesis is a direct ‘sandwich’ ELISA that detects canine pancreatic 
lipase (cPL) (Figure 1). A sandwich ELISA derives its name from the sandwiching effect of the 
antibodies on the antigen (in this case cPL). Here, the antibody used for capture of the antigen 
is attached to the solid surface of a plate. Once the antigen is bound to the capture antibody, a 
second (conjugated) antibody is used to facilitate detection and quantification. The conjugate 
antibody is linked to horseradish peroxidase (HPO) which exerts its enzymatic effects on an 
added substrate that then changes colour in its presence. The result may be read by eye or a 
spectrophotometer. A spectrophotometer can measure adsorption of light at a specific 
wavelength, yielded by substrate catalysis,, which is then compared to a known calibration 
curve to determine the concentration of the antigen. If read by the eye, the test yields either a 
strong colour (strong positive result, indicting higher levels of cPL), a partial colour indicating a 
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weak positive result, or no colour, interpreted as a negative reading, thereby providing a semi-
quantitative result. Visual interpretation by this method can vary between operators and results 
may be considered subjective in comparison to the spectrophotometric method.  
 
Use of monoclonal antibodies as a single species of immunoglobulin, ensures that the 
interaction between the paratope of the immunoglobulin with the epitope of the antigen is 
consistent. This property enables standardisation between tests. Different monoclonal 
antibodies may be used for the capture antibody (on the solid phase) and the detecting 
antibody, facilitating an orientation of the antigen that increases the probability that the detecting 
antibody will bind.  
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Serum sample mixed with monoclonal 
anti-cPL antibodies for capture of 
desired antigen (cPL) with HPO attached 
(conjugate). 
Canine pancreatic lipase 
Mixed conjugate and serum sample 
added to ELISA plate for detection. 
Horseradish peroxidase 
HPO 
ELISA plate washed leaving only 
sandwiched cPL and removing unwanted 
HPO. 
Chromogen added. Enzymatic process 
with horseradish peroxidase causes 
colour change. 
Optical density of colour change 
quantified visually or by 
spectrophotometry for concentration 
determination of cPL. 
Monoclonal anti-cPL antibodies attached 
to ELISA plate (the solid phase). 
Figure 2.1: An illustration of the direct sandwich ELISA technique used for detection of canine 
pancreatic lipase 
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2.5.7.2 Measurement of cPL by radioimmunoassay (RIA)  
 
The canine pancreatic lipase gene was first sequenced by Mickel et al. (1989). The protein itself 
was purified by Steiner and colleagues in 2002. In their study, antisera against canine 
pancreatic lipase (cPL) and canine gastric lipase (cGL) was obtained by inoculating rabbits with 
purified cPL and cGL.  Sacrificed dogs from an unrelated study allowed for application of these 
antibodies to a wide variety of canine tissues including striated muscles, skin, eyes, cerebral 
cortex, cerebellum, medulla, hypophysis, spinal cord, thyroid gland, parathyroid glands, adrenal 
glands, lymph nodes, spleen, cardiac muscle, aorta, vena cava, epiglottis, trachea, bronchi, 
lungs, kidneys, urinary bladder, salivary glands, tongue, oesophagus, stomach, all sections of 
the small intestine, colon, liver, gall bladder, pancreas, prostate, and testes. Only pancreatic 
acinar cells had positive immunofluorescence for cPL. The conclusion by the authors was that 
there is exclusive expression of cPL in the pancreas only, and the high specificity of their 
antibodies meant that there was no cross-immunoreactivity with other lipases. 
 
In the following year, Steiner et al. (2003) reported the development of a radioimmunoassay 
(RIA) for the measurement of cPL in an attempt to circumvent the need for catalytic assays that 
could not discriminate between different lipases from different tissues. Antibodies against cPL 
obtained from rabbits were iodinated with I
125
. A reference range was obtained from 47 healthy 
dogs using the central 95
th
 percentile as 4.4 to 276.1μg/L. Difficulties encountered with this 
assay included limited accuracy in the high end of the working range, but sample concentrations 
were consistently overestimated by the RIA in this range which would not negatively impact on 
its clinical application. Limited precision and reproducibility in the low end of the working range 
was also noted, but was tested at very low concentrations with a working range of 1 to 863 μg/L. 
Again, the clinical relevance of this issue was questionable. Although the RIA for cPL was 
validated, the practicality of working with radioactive materials was a major disadvantage. 
Radioactive materials used in this assay are a cause for concern in regard to safety of 
laboratory personnel, public perception, and regulatory restrictions on laboratories using this 
technology. An alternative was sought for commercial viability that brought about the 
emergence of the ELISA cPLI test. 
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2.5.7.3 Canine Pancreatic Lipase Immunoreactivity 
(cPLI) 
 
The canine pancreatic lipase immunoreactivity (cPLI) test, based on ELISA methodology, was 
the forerunner of a now well-established commercial variant, the canine specific pancreatic 
lipase assay (Spec cPL
®
 ELISA, Idexx Laboratories, see Section 2.5.7.4). For the development 
of the cPLI, purified cPL was obtained from sacrificed dogs and antiserum directed against cPL 
was developed in rabbits, as described above. Purified rabbit polyclonal antibodies were bound 
to microtitre plates and used to capture cPL. Purified polyclonal antibodies were also 
biotinylated, where biotin (vitamin B7) is attached covalently to the antibody and used to detect 
cPL already captured by the antibody bound to the microtitre plates in a sandwich ELISA. This 
process of detection was enabled by streptavidin, a protein derived from the bacterium 
Streptomyces avidinii, which has an extremely high affinity for a non-covalent bond with biotin. 
Streptavidin labelled with HPO and a suitable substrate/chromogen could then be used for 
visual detection of the sandwiched cPL, and the optical density of the reaction determined. A 
standard curve of optical densities for various concentrations of cPL was derived using known 
concentrations of cPL. Sensitivity, working range, accuracy, precision, and reproducibility were 
all validated for the assay. Seventy-four healthy dogs were used to establish the normal 
reference interval, which was taken from the central 95
th
 percentile of the group, and found to be 
2.2 to 102.1μg/L (Steiner et al., 2003).  
 
The reference intervals between the RIA and ELISA (cPLI) were compared and have been 
reported to differ (Steiner et al., 2003). It was noted that the reference populations were 
different, but when healthy dogs from a single population were compared, the RIA values were 
consistently higher (Steiner et al., 2003). Although the authors acknowledged that different 
immunologic assays for the same substance can produce different results, correlation between 
the assays was high with a Spearman coefficient r = 0.9708 (Steiner et al., 2003). The 
explanation offered by the authors alluded to steric hindrance when pancreatic lipase is fixed to 
the bottom of the wells of the ELISA plates. The cPLI has shown good reproducibility, ease of 
performance, cost effectiveness, long-term stability, has no requirement for radioactive 
materials, and is better suited to discriminating dogs with exocrine pancreatic disorders. 
Therefore, the cPLI ELISA superseded the RIA. 
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The cPLI has not been subjected to extensive, rigorous and independent evaluation. These 
researchers produced an abstract evaluating the cPLI in dogs with naturally occurring 
pancreatitis confirmed by histopathology (Steiner et al., 2001). When compared to the control 
population of 74 dogs, 11 dogs with histologically confirmed pancreatitis had a median cPLI 
value of 676.8μg/L, which was significantly higher than the control group of 16.3μg/L. The cPLI 
was also above the upper limit of the reference range of 102 μg/L in all dogs (n=11). For the 
diagnosis of pancreatitis, the authors decided an empirical cut-off value of 250μg/L, yielding a 
sensitivity of 81.8% in 9 of 11 dogs with pancreatitis (Steiner et al., 2001). 
 
Studies investigating the utility of the cPLI in dogs that have clinical signs consistent with 
pancreatitis are scarce. Of 22 dogs with macroscopic evidence of pancreatitis presented for 
necropsy, where the diagnoses were unknown, 20 had clinical signs that could have been 
attributable to pancreatitis such as vomiting, abdominal pain, anorexia and diarrhoea (Steiner et 
al., 2008). Sensitivity of the cPLI in this group of dogs was determined to be 63.6%. Steiner et 
al., (2008) argued that while the number of dogs in the study was low, nearly 82% of dogs had 
mild histopathologic evidence of pancreatitis and none had severe pancreatitis using the scoring 
system that was developed by Newman et al., (2006). 
 
The specificity of the cPLI has been investigated in a single study. Gastritis was confirmed in 25 
dogs by biopsy and subsequent serum testing of cPLI was performed on each dog. Of 25 dogs 
with biopsy confirmed gastritis only 1 had cPLI above the cut-off for pancreatitis (>200μg/L) 
(Steiner 2000). None of these dogs had pancreatic histology performed to rule in or out 
pancreatitis (refer to the earlier section on ‘gold standard’ diagnosis of pancreatitis).  
 
Another retrospective study that has investigated the use of cPLI in dogs with confirmed 
diseases other than pancreatitis evaluated dogs with histologically confirmed inflammatory 
bowel disease (IBD) (Kathrani et al., 2009). A cPLI concentration above the reference interval 
was identified in 32% (15/47) of dogs with IBD, with a mean value of 427μg/L, which is above 
the manufacturer’s cut-off concentration for pancreatitis. The remainder of samples had 
concentrations within the normal reference range. Only 20% (3/15) of dogs with cPLI 
concentration above the reference range had ultrasonographic evidence of pancreatitis and no 
dogs with a low cPLI concentration showed ultrasonographic evidence of pancreatitis. There 
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was no significant difference between these two groups with respect to ultrasound findings. In 
addition, there was no significant difference in histology severity for IBD between the groups. 
The authors themselves point out that the clinical signs of pancreatitis and IBD are non-specific 
and easily confused with other conditions. Although the study concluded that a subset of dogs 
with IBD may have subclinical pancreatitis, diagnostics pursued in reverse order may actually 
result in misdiagnosis of IBD for pancreatitis. 
 
The 2010 study by Steiner et al. that investigated the effect of chronic renal failure on serum 
lipase activity (Steiner et al., 2010), also evaluated cPLI. Only 12.5% (2/16) of dogs had cPLI 
concentrations above the reference interval and none were above a suggested cut-off for 
pancreatitis of approximately twice the reference range. However, cPLI was significantly higher 
in dogs with experimentally induced renal failure than the control group. The authors concluded 
that these elevations in canine pancreatic lipase concentration were not clinically relevant. The 
stability of cPL over 20 years stored at minus 80 degrees Celsius is unknown. 
 
The issue of canine pancreatic lipase stability after storage of samples, or testing of samples by 
laboratories after interstate transport, needed to be addressed. Thus the stability of canine 
pancreatic lipase was investigated in serum samples stored at a variety of temperatures over a 
time period of 21 days (Steiner et al., 2009). On days 0, 3, 7, 14, and 21, at temperatures of 
24°C, 4°C, -20°C, and -80°C, samples from 8 randomly selected dogs were tested for cPLI. No 
significant variation was found over 21 days for individual dog’s serum samples. However, a 
larger variation between results was found at low and high mean concentrations of canine 
pancreatic lipase. The highest mean concentration of 407.8 μg/L was well above the reference 
interval of 2.2-102.1 μg/L and the variation between results at this concentration was 
determined to be a mean of only 20.8 μg/L. This is unlikely to have a significant clinical impact 
on decision making, although the cPLI test never went on to be used commercially. The authors 
also compared 30 paired serum and plasma samples from randomly selected dogs and 
reported no difference in the median values of cPL and a strong correlation of r = 0.977 
between serum and plasma cPL concentrations.  
 
Steiner et al. (2009) continued their investigations into the purported benefits of the 
measurement of canine pancreatic lipase compared with non-specific catalytic assays for 
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general lipase. Since lipase activities derived by catalytic assays increase with glucocorticoids, 
the effect of prednisone on serum cPL, as measured by cPLI, was also assessed. Pre-treatment 
samples were obtained from 6 dogs on days 0 and 14 and subsequent samples were obtained 
on days 28 and 42 after administration of 2.2 mg/kg prednisone per day from day 15 to 42. 
Additional samples were obtained on days 56 and 70. No samples were recorded with cPLI over 
the reference interval and the mean cPLI concentrations for all dogs over all days did not differ 
significantly, thus, establishing another benefit of cPL over general lipase measurement. 
 
As the cPLI assay uses small scale manufacturing processes not suitable for commercialisation, 
another ELISA was developed to circumvent this. It was then called the canine specific 
pancreatic lipase test (Spec cPL
®
), which incorporates dual monoclonal antibodies derived from 
mice (Huth et al., 2010). Further, a rapid in-clinic semi-quantitative assay (SNAP
®
 cPL) has also 
been developed using the same dual monoclonal antibodies for capture and detection of 
pancreatic lipase as the Spec cPL
®
. 
 
2.5.7.4 Canine specific pancreatic lipase (Spec cPL®) 
The Spec cPL
®
  was developed by Idexx Laboratories for its suitability in commercial application 
(Huth et al., 2010). During development, a recombinant antigen was synthesised for use instead 
of cPL (rcPL) (Beall et al., 2010). Mice were immunised with purified native canine pancreatic 
lipase (cPL) and 2 monoclonal antibodies were obtained for the capture and conjugated phases 
of the ELISA (Huth et al., 2010). A sandwich ELISA for Spec cPL
®
 was developed; optical 
densities were derived from an HPO detection system and a standard curve was constructed 
from known concentrations of cPL. The original ELISA, the cPLI, was used as the gold standard 
assay. Analysis of the performance of the Spec cPL
®
 by Idexx Laboratories showed reliability 
for a dynamic range of cPL concentrations 36 to 954μg/L. Intra- and inter-assay variability was 
analysed over this range, with production of acceptable coefficient of variations for ELISA 
technology. It was also determined that bilirubin, haemolysis and excess lipid, at concentrations 
consistent with canine pancreatitis, did not affect the results (Huth et al., 2010). In addition, any 
variability was thought comparable to the cPLI assay, though, a bland-Altman plot comparing 
the assays showed the Spec cPL
®
 to read consistently higher at concentrations above 200μg/L, 
which is the upper limit of the reference range. The authors concluded that this bias was 
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clinically irrelevant as it occurred higher that the reference interval. However, Idexx Laboratories 
(McCord et al., 2009, Beall et al., 2011) have adopted the following guidelines for interpretation 
of Spec cPL
®
 results: 
 
 Normal animals - reference interval 0 to 200μg/L,  
 Equivocal - if results fall between 200 to 400μg/L, and  
 Consistent with pancreatitis - results of cPL at concentrations > 400μg/L 
 
The specificity of the Spec cPL
®
 has been investigated in two recent studies. The first by 
Neilson-Carley et al. (2011), involved dogs of varying health status, the majority of which were 
obtained from an animal shelter (27/42), with the remaining 15 dogs used from a referral 
hospital with disease states including dystocia, neoplasia, anaemia, and trauma. Histological 
assessment was based on 1-2cm interval slices of all pancreata. Ninety-five percent (40/42) of 
these dogs revealed no lesions compatible with pancreatitis. Spec cPL
®
 concentrations in 95% 
(38/40) of these dogs were below the upper reference limit of 200 μg/L, yielding a specificity of 
95%. Only one of the 2 remaining dogs had a Spec cPL
®
 above 400 μg/L, which is consistent 
with pancreatitis. This dog was young and the only abnormality detected was 
haemoconcentration. It had no evidence of pancreatic inflammation and was from the animal 
shelter. The authors conceded in their discussion that this population of dogs would be unlikely 
candidates for the Spec cPL
®
 test, as they exhibited no clinical signs of pancreatitis. Therefore 
the authors could only conclude that the cut-off values used may be useful for diagnosing 
pancreatitis in dogs with a lack of histopathologic lesions consistent with pancreatitis, and for 
which pancreatitis is not considered a major differential diagnosis. They also recommended 
further studies to evaluate specificity of this test in a population of dogs where pancreatitis is 
considered a differential diagnosis. 
 
The second study evaluating Spec cPL for its specificity performed histological examination on 
3 sections of canine pancreas to confirm pancreatitis (Mansfield et al., 2012). A new scoring 
system for histological pancreatitis was proposed in this study (and was described previously – 
section 2.5.2). Of 32 dogs included in the study, 20 were classified as having subclinical 
pancreatitis of no clinical relevance. Using cPL cut-off concentrations of 200 and 400 µg/L, there 
were 4 and 2 false positive results, yielding a specificity of 80% and 90% respectively. The 
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remaining 12 dogs had a histopathologic diagnosis of pancreatitis. Using the same cut-off 
values (200 and 400 µg/L) for cPL, there were 7 and 4 true positives, respectively, yielding a 
sensitivity of 58% and 33%, respectively. Of all the dogs designated true positives (7 dogs), only 
3 had pancreatitis as the primary cause of their clinical signs. 
 
Trivedi et al. (2011) evaluated both the sensitivity and specificity of the Spec cPL
®
 in 70 dogs 
with and without histopathologic evidence of pancreatitis. This study also enrolled dogs that 
were euthanized for a variety of reasons, and required collection of a serum sample within 24 
hours before euthanasia and the removal of the entire pancreas for histopathologic evaluation 
within 4 hours of euthanasia. Necropsy was performed on 69 of 70 dogs enrolled. 
Histopathologic evidence of mild pancreatitis was observed in 56 of 70 dogs, moderate 
pancreatitis in 6 of 70 dogs, and severe pancreatitis in 1 of 70 dogs. Of the 7 dogs with no 
histopathologic evidence of pancreatitis, only 1 had a Spec cPL
®
 above 200 μg/L, which was 
also below the cut-off for being consistent with pancreatitis (400 μg/L). The study also showed 
that the correlation between histopathologic indicators of acute pancreatitis, such as 
suppurative inflammation, peripancreatic fat necrosis and acinar cell necrosis, and the Spec 
cPL
®
 concentration were stronger than those for chronic pancreatitis, such as pancreatic fibrosis 
and atrophy. However, nearly all dogs in this study with acute pancreatitis had evidence of 
chronic pancreatitis and could not be considered separately. When the authors used the 
manufacturer’s recommended cut-off of 400 μg/L, the sensitivity for mild pancreatitis was only 
21% (12/56), and when using 200 μg/L was 43% (24/56) (Trivedi et al., 2011). When applied to 
the moderate-to-severe group for cPL concentrations, 71% (5/7) was obtained for both cut-offs. 
The authors noted that the strict nature of the histological scoring system used might have 
contributed to a poor sensitivity for dogs with mild pancreatitis. This system required any dog 
with 1 or more lesions in any section of the pancreas to be classified as mild pancreatitis, 
despite the authors’ suspicions that this may represent normal variation. Specificity for a cut-off 
concentration of greater than 400 μg/L was 100% (7/7) for both mild and moderate-to-severe 
pancreatitis, and 86% (6/7) for both these groups using a cut-off of greater than 200 μg/L. 
Interestingly, this study also reported that only 65% (11/17) of dogs with Spec cPL
®
 
concentrations greater than 400μg/L exhibited clinical signs consistent with pancreatitis, such as 
vomiting and anorexia.  Further, only 35% (6/17) displayed abdominal pain on physical exam. 
The diagnoses assigned to the dogs included in this study were unknown and the authors 
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acknowledged that they were necropsied for a variety of reasons. The majority of cases were 
mild, which may have skewed the sensitivity data. Importantly, 21% (12/56) of dogs with mild 
histologic evidence of pancreatitis had a Spec cPL
®
 > 400 μg/L (consistent with pancreatitis), 
and all of them had histological evidence of hepatopathy. Three of these dogs had histologic 
evidence of intestinal lesions. Only one dog in this subgroup had macroscopic evidence of 
pancreatitis. The authors recommended further assessment of the Spec cPL
®
 in dogs with 
extra-pancreatic disease, especially those with hepatopathy. 
 
In the study by Steiner et al., (2006) including dogs with macroscopic pancreatitis, the sensitivity 
of the Spec cPL
®
 was 63.6%. As specified earlier, the authors believed this low sensitivity may 
be a reflection of the mild scoring of pancreatitis. They also pointed out that the cPLI and Spec 
cPL
®
 had the highest sensitivity for detecting pancreatic inflammation than the other tests 
evaluated; serum amylase, lipase, cTLI and trypsin alpha 1 proteinase inhibitor.  
 
McCord et al., (2012) introduced the assessment of the Spec cPL
®
 for sensitivity and specificity 
in diagnosing acute pancreatitis in dogs that presented with an initial differential diagnosis of 
acute pancreatitis. The history, physical exam, laboratory findings, abdominal ultrasound and 
clinical course were assessed by 4 internists blinded to the Spec cPL
®
 results. Still ultrasound 
images were reviewed by a board certified radiologist. These dogs were then assigned to 1 of 5 
groups of either not pancreatitis (group 0), not primary pancreatitis (group 1), possibly 
pancreatitis (group 2), probably pancreatitis (group 3), or pancreatitis (group 4). A control group 
of dogs deemed not to have pancreatitis was also included for categorization into these 5 
groups. There was a high level of agreement in the categorization between internists for 
grouping, with a kappa value of 0.87. Sensitivity and specificity were reported for the Spec cPL
®
 
as 78 and 88% respectively using 400 µg/L cPL as the cut-off. The authors concluded that the 
test was superior to amylase and lipase for the diagnosis of pancreatitis, and further, that dogs 
with Spec cPL
®
 values under 200 μg/L were unlikely to have pancreatitis. The study lacked 
histopathologic evaluation of pancreata for all dogs bar 3. This study draws attention to the 
notion of non-primary pancreatitis, where it may run concurrent to a more clinically relevant 
disease process. That is, dogs with extra-pancreatic disease, or disease that does not originate 
under the umbrella term of pancreatitis, may develop inflammatory infiltrates of the pancreas 
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secondary to the nature of the inciting disease. This has not been thoroughly investigated as far 
as the Spec cPL
®
 is concerned. 
 
2.5.7.5 SNAP® cPL 
 
Idexx Laboratories developed a semi-quantitative immunochromatographic version of the Spec 
cPL
®
, the SNAP
®
 cPL, in order to offer an in-house test that provides an immediate result for 
use in emergency settings. The SNAP
®
 cPL test is registered to screen dogs for pancreatitis 
when they present to a veterinary care facility, with subsequent follow up by Spec cPL
®
 
quantification. 
 
A brief communication by researchers at Idexx Laboratories (Beall et al., 2011) has been 
published on the performance of the in-clinic SNAP
®
 cPL. The SNAP
®
 cPL is described as a 
semi-quantitative assay which generates a coloured test spot on a bench top device that is 
compared visually to the reference spot. If the test spot is the same colour intensity or darker 
than the reference spot, the test is determined to have a concentration of cPL greater than 200 
μg/L and is therefore deemed to be positive, or abnormal. The cut-off value of 200 μg/L was 
selected so that fewer dogs with elevated cPL would go undetected. The manufacturer advises 
that a positive SNAP
®
 cPL results is then followed by the Spec cPL
®
 to derive an absolute 
value. The perceived benefits of the SNAP
®
 cPL include its rapid test time in the clinic and ease 
of use. 
   
The SNAP
®
 cPL test was developed from the same ELISA technology used for the Spec cPL
® 
, 
using the same two monoclonal antibodies to capture and detect cPL for the test ‘spot’. A pre-
determined volume of canine serum is added to a solution containing chromagen-conjugated 
antibodies against cPL, and the mixture is then added to the testing device. The mixture flows 
along the solid phase support matrix, which allows the cPL-antibody complex (if present) to bind 
to the solid phase capture anti-cPL antibody. When the mixture reaches a certain distance along 
the solid phase, the device is depressed to allow release of a wash solution followed by a 
substrate solution (3,3’,5,5’-tetramethylbenzidine), back through the matrix. The reference spot 
on the solid phase of the test comprises chicken immunoglobulin G (IgG) that is recognised by a 
goat-derived anti-chicken IgG antibody in the liquid phase reagents, and serves as an internal 
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control, generating a fixed colour intensity regardless of the canine serum sample. This colour 
intensity is designed to match a sample containing approximately 200 μg/L cPL. The liquid 
phase antibodies are conjugated to horse radish peroxidase for the colorimetric interpretation, 
using the substrate 3,3’,5,5’-tetramethylbenzidine, producing a blue colour. 
 
Recombinant cPL (rcPL) was used to calibrate the test. The reference standards contain rcPL at 
0, 100, 200, 500, 1000 μg/L. The colour intensity produced by the standards is measured by a 
reflective densitometer to generate readings for known rcPL concentrations. Densitometer 
colour intensity ratios of known rcPL concentrations, to reference spot concentrations, for each 
of the known rcPL samples were used to produce a calibration curve. This enables estimation of 
an unknown canine serum cPL concentration using the optical density ratio derived from the 
patient’s test spot compared to the reference spots. In essence, a progressively darker test spot 
is a reflection of a higher concentration of cPL in the sample. The use of a reflective 
densitometer can then derive a specific concentration for the sample based on the difference 
between the test spot and the reference spot. 
 
Several testing conditions were used to evaluate the clinical utility of the SNAP
®
 cPL; it was 
determined that commonly encountered serum components in dogs with pancreatitis, such as 
increased bilirubin, lipid and haemoglobin, did not interfere with the test results (Beall et al., 
2011). The visual results of the SNAP
®
 cPL were also shown to be precise with 5 canine 
samples of known cPL concentrations, tested 10 times each on 3 separate days, for a total of 
150 tests. The test was consistent for 149 of the samples when using a densitometer and 
agreed with the Spec cPL®  on all 149 occasions.  
 
Further, the visual results of the SNAP
®
 cPL were assessed for its agreement with the Spec 
cPL® using three separately prepared batches of the SNAP
®
 cPL on 49 canine samples (Beall 
et al., 2011). A broad distribution of cPL concentrations was determined by theSpec cPL
® 
 
reference method and run in duplicate, with the mean concentration used to calculate the 
agreement. The authors reported 96-100% and 88-92% agreement for the normal and 
abnormal samples, respectively (Beall et al., 2011). The kappa coefficient showed a very good 
agreement (κ=0.878) between the SNAP
®
  and Spec cPL®  tests, and was further confirmed by 
a correlation coefficient of r = 0.92 to 0.948. It was noted that samples determined by the Spec 
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cPL®  as >200 μg/L but <300 μg/L, could be reported as ‘normal’ on the SNAP
®
 cPL, possibly 
due to a visual discordance, as the test and reference spots were nearly identical. These 49 
samples were run once on each of 3 batches of SNAP
®
 cPL and duplicate on one batch. 
Results showed good correlation between batches and between duplicates within the batch.   
Interestingly, the visual results for a 214 μg/L serum pool and the 200 μg/L rcPL pool were split 
between abnormal and normal, with approximately 30% reading as normal throughout testing. It 
was concluded that samples with concentrations approximating the cut-off for abnormal may be 
difficult to interpret due to subjective evaluation. 
 
The stability of the SNAP
®
 cPL assay itself when stored at 2-7°C was also tested over 15 
months at months 1, 2, 4, 6, 8, 10, 12, 15, using rcPL and serum cPL, and there was no 
difference compared to  baseline, making the test stable for storage over this time period 
(Steiner et al., 2009). 
 
A single study (McCord et al., 2012) has evaluated the sensitivity and specificity of the SNAP
®
 
cPL in dogs that presented to multiple veterinary centres with, and without, a differential 
diagnosis of pancreatitis. All dogs were allocated to groups based on the likelihood of the 
presence or absence of pancreatitis by 4 Board-certified internists. Ultrasound examinations 
were performed in each case, but not always by a veterinary radiologist. However, still images 
were evaluated by the radiologist in each case. Of 84 dogs evaluated, 57 dogs had suspected 
pancreatitis. However, pancreatitis in 37 of these 57 dogs was still considered unlikely; these 
individuals were determined to have a convincing primary alternative disease present to explain 
the clinical findings. The remaining 20 dogs fell into 3 groups of “possible pancreatitis” (n= 9), 
“probable pancreatitis” (n=8) and “definite pancreatitis” (n=3) and were used to determine the 
sensitivity of the tests. The group with “possible pancreatitis” had inconsistent 
clinicopathological evidence supporting the diagnosis and no ultrasonographic evidence of 
pancreatitis, but no alternative disease could be determined. The group “probable pancreatitis” 
had supportive clinicopathological and ultrasonographic abnormalities, but did not have 
cytological or histopathologic evidence to support a diagnosis. Only the remaining three (of 20) 
dogs demonstrated cytological or histopathologic evidence of pancreatitis. The sensitivity and 
specificity of the SNAP
®
 cPL was determined to be 94 and 77.5% respectively. The authors 
noted the important influence of the relationship between the prevalence of pancreatitis and the 
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predictive values of the tests. To emphasise this point they stated that using laboratory tests to 
aid the diagnosis of acute pancreatitis where the index of suspicion for the disease is low, could 
result in false positive results. The authors also concluded the reverse to be true in dogs. The 
predictive value is likely to be low when the index of suspicion for acute pancreatitis is high in 
conjunction with a negative test result (McCord et al., 2012). 
 
Despite the SNAP
®
 and Spec cPL® tests showing promise in their ability to identify the 
presence of cPL, their capacity to identify acute pancreatitis appears far from conclusive. Non-
specific lipase activity may increase with acute pancreatitis, but it has been shown to be too 
inaccurate for clinical application. This may equally be true of cPL. It is hypothesised that cPL 
serum concentration may fluctuate with primary pancreatic disease as well as local or systemic 
disease that may impact directly on the pancreas. The relationship of cPL concentration with 
acute abdominal disease in dogs requires further investigation. 
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CHAPTER 3: APPLICATION OF STATISTICAL METHODS TO 
THE DIAGNOSIS OF CANINE ACUTE PANCREATITIS 
 
3.1 Introduction 
 
Accurate diagnosis relies on the clinician’s ability to assimilate a spectrum of data, generated 
from a subject’s problem list, and choose the most likely explanation for the subject’s problems. 
The process of arriving at the diagnosis relies on applications of probabilities, or likelihoods, of 
the changes recognised in the data to fit with the diagnosis. These probabilities are based on 
previous studies that characterise the pathophysiology, and the pattern of clinical signs, 
progression and outcome. The purpose of reaching a diagnosis is to create an opportunity to 
intervene and change the outcome, or establish a prognosis.  
 
Selection of an appropriate test for deriving a diagnosis is based on assessment of the 
diagnostic accuracy of a test, its sensitivity and its specificity. Certain conditions can make it 
difficult to establish the sensitivity and specificity of a diagnostic test, one of which is the 
absence of a gold standard. The application of diagnostic tests for the diagnosis of canine 
pancreatitis is impeded by certain conditions, many of which have been discussed in Chapter 2. 
This chapter will summarise these difficulties as they apply to the statistical methods used for 
assessing a diagnostic test.  
 
3.2 Sensitivity and specificity 
 
Sensitivity is the proportion of subjects with the target disorder that have a positive test result 
(Haynes et al., 2006). Specificity is the proportion of subjects without the target disorder that 
have a negative test result (Haynes et al., 2006). A test with a high sensitivity will detect most 
subjects with the target disorder and is preferred for a diagnostic test. A test with high specificity 
will detect most subjects without the target disorder and is preferred for a screening test 
(Haynes et al., 2006). Ideally, a test would have both high sensitivity and specificity, making the 
test highly accurate.  
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The determination of sensitivity and specificity for any given study is reliant on the population in 
which the test is being conducted, in particular the prevalence of the target disorder. In addition, 
the evaluation of the test in question should be compared against the “gold standard”, that is, 
the testing method that confirms the true presence or absence of the target disorder in the 
population. Thus, the two key factors required for unbiased estimations of sensitivity and 
specificity are (1) selection of an appropriate sample population, and (2) comparison with a 
‘gold’ standard.  
 
3.3 Selection of the appropriate ‘intended use’ population 
 
The challenge of evaluating a test in the clinical setting is that there may be a variety of 
diseases that present with similar signs. The important question is whether the test can 
discriminate between subjects that are suspected to have the disease, which do not, and those 
that do have the disease. Ideally, the population of individuals used to determine a test’s 
operating characteristics should be similar to the population in which the test will be used, and 
should include individuals that display a broad spectrum of clinical features of the disease in 
question, from mild to severe (Haynes et al., 2006). 
 
To illustrate this point, design-related bias occurs if selection of a normal population without the 
disease is compared with subjects that have severe forms of the disease; this may over-
estimate the power of the test. One example of a study with design-related bias from the 
literature pertaining to the diagnosis of pancreatitis is by Neilson-Carley et al. (2011). These 
authors compared a cohort of dogs (27/42) obtained from an animal shelter as their normal 
population (i.e. a group expected to have a low prevalence of pancreatitis) with the remaining 
15 dogs that were sourced from a referral hospital, with varying disease states. These 
circumstances may lead to an over-estimation of the specificity of the test. In another study, 
Trivedi et al. (2011) also included a cohort of dogs that was not the intended-use population. 
The entire cohort appeared to consist of sick dogs with a broad spectrum of disease and only 
65% of these dogs had clinical signs consistent with pancreatitis. A further limitation of this 
study was that most of the dogs had only mild pancreatitis on histopathology, which may have 
also skewed the sensitivity and specificity data. 
47 
 
 
Similar challenges in study design make it difficult to assess the diagnostic accuracy of the Spec 
cPL®  and SNAP
®
 cPL. An ideal population to evaluate the test would be one that comprised 
dogs with signs of acute abdominal disease, and included individuals with pancreatitis that 
showed a broad spectrum of severity. One further, common hindrance to any study involving 
dogs with pancreatitis is the small sample size, which is usually due to the difficulty of obtaining 
a definitive diagnosis, that is, a gold standard result 
 
3.4 The role of the gold standard in test evaluation 
 
A ‘gold’, or reference, standard must provide definitive diagnosis of the disease in question, and 
is generally more time-consuming, expensive, invasive or otherwise difficult to perform than the 
test being compared to it; hence the motivation for development of the test (Haynes et al., 
2006). Sometimes the gold standard cannot be obtained in client-owned subjects, for example, 
when necropsy is required. It is common in clinical studies to use a composite reference 
standard, which may be a combination of other tests and expert opinion (Reitsma et al., 2009). 
As discussed previously (Section 2.5.2), the traditionally accepted gold standard for acute 
pancreatitis is presence of inflammation within the pancreas viewed on light microscopy 
examination of tissue sections. It can be difficult to apply the stringent histopathological scoring 
systems that have been developed for acute pancreatitis, as these can only be achieved from 
tissue samples harvested at necropsy. Therefore, using a population of subjects that underwent 
necropsy not only limits sample size, but also may introduce bias towards a population of more 
severely affected subjects.  
 
Given the difficulties of applying the gold standard to studies evaluating acute pancreatitis, it 
may be better to apply a composite reference standard that includes data such as history, 
physical examination, ultrasonography and other clinico-pathologic test results. This would rely 
on systematic expert review being employed to confirm the clinical diagnosis. Unfortunately, 
there is no consensus currently on such a reference standard, and therefore the disease is 
variably defined within the literature (as previously discussed).  
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This problem of lack of a gold standard for an appropriate sample population brings into 
question the validity of using sensitivity and specificity as appropriate measures of a diagnostic 
test’s merit for pancreatitis. It may be that measures of agreement, such as Cohen’s kappa 
statistic, with clinical diagnosis may be more useful and provide a more relevant interpretation. 
Cohen (1960) stated that for any problem in nominal scale agreement between two judges, 
there are only two relevant quantities: po = the proportion of units in which the judges agreed, 
and pc = the proportion of units for which agreement is expected by chance. Therefore Cohen’s 
kappa is used to determine the degree of agreement between two observers or tests, taking into 
account that some agreement may occur by chance. This also allows for a comparison to the 
presence of a clinical syndrome rather than a gold standard. In the case of acute pancreatitis, it 
may be present but may not be the primary reason for the subject being ill. Therefore, 
characterising that the subject is showing the clinical syndrome of acute pancreatitis, rather than 
another serious illness that is causing some degree of pancreatitis, is vital in order to determine 
a further diagnostic or treatment plan.  
 
Given the inherent difficulties of interpreting the results of evaluation of diagnostic test accuracy 
of Spec cPL
®
 and SNAP
®
 cPL in the literature, our goal therefore was to demonstrate the 
limitations of these tests applied to an appropriate sample population and compare results of 
these tests to a composite reference standard that represented a clinical diagnosis, rather than 
the historical gold standard.  
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CHAPTER 4:  DIAGNOSTIC ACCURACY OF THE SNAP AND 
SPEC CANINE PANCREATIC LIPASE (CPL) TESTS FOR 
PANCREATITIS IN DOGS PRESENTING WITH CLINICAL SIGNS 
OF ACUTE ABDOMINAL DISEASE. 
 
(This chapter describes the clinical research project undertaken for the RMT degree, and forms 
the text of the following publication: Haworth MD, et al. (2014). Diagnostic Accuracy of the 
SNAP and Spec Canine Pancreatic Lipase (cPL) Tests for Pancreatitis in Dogs Presenting with 
Clinical Signs of Acute Abdominal Disease J Vet Emerg Crit Care. In Press.) 
 
4.1  Introduction 
Acute pancreatitis (AP) is an important disease of dogs, with variable and non-specific clinical 
signs such as abdominal pain, vomiting and diarrhea (Cook et al., 1993; Hess et al., 1998).
 
These clinical signs are also present in conditions such as septic peritonitis or intestinal 
obstruction, which require specific and timely interventional treatment. Traditional diagnostic 
methodologies, such as total serum lipase and amylase, have poor sensitivities and specificities 
for the diagnosis of AP in dogs (Mansfield et al., 2000; Steiner et al., 2008; Trivedi et al., 2011). 
 
The canine pancreatic lipase test measures lipase that originates in the pancreas, and 
theoretically should only be increased during times of pancreatic inflammation (Steiner et al., 
2003)
.
 The canine pancreatic lipase immunoreactivity (cPLI) assay (first a radioimmunoassay, 
and subsequently an enzyme immunoassay) has been validated in dogs (Steiner et al., 2003). 
The cPLI assay was then developed into a commercially available specific canine pancreatic 
lipase (Spec cPL) assay, using a recombinant peptide as the antigen and dual monoclonal 
antibodies for capture and detection (Huth et al., 2010). Spec cPL shows good correlation to 
and high reproducibility with cPLI (Huth et al., 2010). Spec cPL results < 200 µg/L are 
considered to be consistent with an absence of pancreatic inflammation (Huth et al., 2010; 
McCord et al., 2012), while results ≥ 400 µg/L are considered consistent with a diagnosis of 
pancreatitis, and a result in the range 200-399 µg/L is considered equivocal (Steiner et al., 
2001; McCord et al., 2012). A rapid in-clinic semi-quantitative assay (SNAP cPL) has also been 
developed using the same dual monoclonal antibodies for capture and detection of pancreatic 
lipase as Spec cPL (Steiner et al., 2001). SNAP cPL is reported to show good correlation and 
reproducibility compared to the laboratory-based Spec cPL (Steiner et al., 2001). A negative 
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SNAP cPL result corresponds to a Spec cPL concentration < 200 µg/L, and a positive result 
with a concentration ≥ 200 µg/L (Steiner et al., 2001). 
 
The reported sensitivity for cPLI/Spec cPL ranges from 21-82% (Steiner et al., 2001; Steiner et 
al., 2008; Trivedi et al., 2011;  McCord et al., 2012; Mansfield et al, 2012), whilst specificity for 
Spec cPL is reported to range from 86-100% (Trivedi et al., 2011; McCord et al., 2012; 
Mansfield et al., 2012). All but one of these studies based a diagnosis of AP on histological 
demonstration of pancreatic inflammation. As a result, the sensitivities and specificities may not 
be accurate as pancreatic inflammation was often very low or mild. The sensitivity of Spec cPL 
(or cPLI) has been shown to be higher in dogs with increasing histological severity (Newman et 
al., 2004; Steiner et al., 2008; Trivedi et al., 2011). A recent study reported the sensitivity and 
specificity of the SNAP cPL to be 94% and 77% respectively in dogs that presented both with 
suspicion and without suspicion of pancreatitis (McCord et al., 2012). 
 
The true diagnostic accuracy of non-invasive methodologies for AP is unknown due to the 
difficulty in obtaining a gold standard. Abdominal ultrasound is used extensively in veterinary 
practice. The main finding in acute pancreatitis is peri-pancreatic hyperechogenicity associated 
with peri-pancreatic fat necrosis in the acute necrotizing form (Hecht et al., 2007). Pancreatic 
inflammation may also develop due to duodenal reflux, ischemia or generalized peritonitis in 
association with other diseases such as septic peritonitis, abdominal hemorrhage or intestinal 
foreign bodies. Therefore, despite the presence of histological and ultrasonographic severe 
pancreatic inflammation, pancreatitis may only be secondary and not be the cause of the clinical 
presentation in dogs. Sensitivity of ultrasound may be influenced by animal factors (obesity, 
ingesta interfering with image quality), operator factors (level of experience) and technical 
factors (ultrasound equipment). Reported sensitivities for ultrasound are 66-68% (Hess et 
al.,1998; Steiner et al., 2008). Higher median histological grading of pancreatic inflammation 
has been reported to correlate with ultrasonographic evidence of pancreatitis (Steiner et al., 
2008). In another recent study, a small subgroup of dogs with histologically confirmed 
pancreatitis of varying severity all had ultrasonographic evidence of pancreatitis (Trivedi et al., 
2011). Therefore history, clinical signs, laboratory testing, and abdominal imaging are often 
used together to make a clinical diagnosis of AP. Conversely, it is also possible that reliance on 
histological evaluation of the pancreas may bias studies towards dogs with more severe disease 
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(and a fatal outcome). Additionally, pancreatic biopsies are seldom obtained in critically ill dogs 
unless at post-mortem, and inflammation may be unevenly distributed throughout the pancreas, 
or just be located in the peri-pancreatic fat (Newman et al., 2004; Hecht et al., 2007).  
 
The primary objective of this study was to determine the accuracy, sensitivity and specificity of 
SNAP cPL and Spec cPL in dogs presenting with acute abdominal disease to an emergency 
centre. A secondary objective of this study was to quantify the agreement between the Spec 
cPL and the SNAP cPL for paired serum samples taken from the same cohort of dogs.   
 
4.2 Materials and Methods 
Client-owned dogs presenting to a first-opinion and referral emergency center at a university 
teaching hospital between March 2009 and April 2010 were recruited. Dogs were initially 
included if they had two or more of the following clinical signs: acute (< 2 days) onset of 
abdominal pain, vomiting, abdominal distension or diarrhea. Dogs were excluded from the 
analysis if they did not have a definitive diagnosis made during hospitalization. 
 
Blood was collected via jugular, cephalic or saphenous venepuncture from all dogs within 24 
hours of admission as part of diagnostic investigation. If additional samples of blood were 
collected specifically for the purposes of the study, signed owner consent was obtained. The 
study was approved by the institutional Animal Ethics Committee, fulfilling NHMRC regulations. 
Two mLs of blood was collected into plain serum tubes initially, centrifuged at 5800 rpm (3120g) 
for 10 minutes, and allowed to equilibrate to room temperature prior to serum collection.  
 
The storage of the SNAP cPL (SNAP cPL Test Kit, Idexx Laboratories Inc., Westbrook, ME) 
kits, sample handling and testing procedure was according to manufacturer’s instructions 
(Packet Insert, Idexx Laboratories Inc., Westbrook, ME). Testing of SNAP cPL was either 
performed at the time of collection and the remaining serum frozen at minus 20°C, or the serum 
sample was kept refrigerated for less than one week and then allowed to equilibrate to room 
temperature before being tested and then frozen. One of two qualified veterinary nurses and 
one of the authors (MH) performed all in-house SNAP cPL testing and were unaware of the final 
diagnoses at the time. Results of the SNAP and Spec cPL tests were not paired with individual 
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dogs at the time a diagnosis was assigned, and the test result was not revealed to veterinarians 
in charge of the clinical case. If the person performing the in-house test was unsure of the result 
due to test and reference spot intensity similarities, the test was repeated. If similar results were 
obtained a second time, the result was recorded as an abnormal. A later batch analysis of Spec 
cPL (Spec cPL ELISA, Idexx Laboratories, Brisbane, Queensland, Australia) concentration was 
performed on the frozen serum that had been stored up to 18 months. This was shipped 
overnight, refrigerated, to a regional laboratory
 
(Idexx Laboratories, Brisbane, Queensland) for 
analysis.  
 
The SNAP cPL was recorded as either visually normal or abnormal, where abnormal is 
equivalent to a canine pancreatic lipase ≥ 200 µg/L. The agreement between a clinical 
diagnosis of pancreatitis and a visually abnormal SNAP cPL was quantified by the kappa () 
coefficient. Further, the agreement between a clinical diagnosis of pancreatitis and a Spec cPL 
≥ 400 µg/L was also quantified by the kappa () coefficient.  A Spec cPL ≥ 400 is considered 
consistent with pancreatitis (Steiner et al., 2001, Trivedi et al., 2011, McCord et al., 2012). 
 
A cut-off concentration of cPL ≥ 200 µg/L, as measured by Spec cPL, was used for the 
agreement between the SNAP cPL and Spec cPL for all dogs. Spec cPL above or below this 
concentration, with visually abnormal or normal SNAP cPL respectively, was considered 
necessary for agreement between the two tests.  
 
All agreements were made using McNemar’s test, and quantified by the kappa () coefficient 
(PROC FREQ, SAS v9.1, SAS Institute, Cary, NC). Results for the Spec cPL were between the 
values of 30 µg/L and 1000 µg/L, which represents the limits of the range reported by the 
laboratory performing the assays. Reported results of ≤ 30 µg/L or  ≥ 1000 µg/L were calculated 
as 30 µg/L or 1000 µg/L respectively for all analyses. 
 
Minimal testing to diagnose dogs with AP included history, physical exam, complete blood 
count, biochemical analysis, and abdominal ultrasound by a veterinary radiologist. Diagnostics 
for dogs without AP were performed as indicated for each individual dog to enable a diagnosis. 
These tests included history, physical exam, complete blood count, biochemical analysis, 
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abdominal ultrasound (by either a veterinary radiologist or emergency clinician), blood gases 
and electrolytes, thoracic and abdominal radiography and computed tomography, 
echocardiography, coagulation function, body fluid analysis and culture and sensitivity, cytology, 
biopsy, histopathology, immunohistochemistry, and surgery. 
  
The results of these tests were reviewed by 3 of the authors (2 board-certified ECC and 1 
board-certified internal medicine) upon completion of the study to determine the definitive 
diagnosis. The authors were blinded to the results of the SNAP and Spec cPL tests at that time. 
Dogs were diagnosed with AP if they had ultrasonographic and/or histological support for 
pancreatic inflammation or necrosis with no other identifiable disease. Supportive 
ultrasonographic evidence of AP was defined and reported by the veterinary radiologist to 
include the presence of an enlarged, hypoechoic pancreatic tissue surrounded by hyperechoic 
peripancreatic mesentery, with or without peritoneal effusion, biliary duct dilatation and 
corrugation or thickening of the duodenal wall (Hess et al.,1998; Hecht et al., 2007). 
Additionally, in order to be given a final diagnosis of clinical AP, a minimum of 6 months follow-
up was required to ensure exocrine pancreatic neoplasia was unlikely.  
 
For analysis, dogs were allocated to one of two groups, based on the above criteria: 
 Group 1: Dogs with AP as their primary disease.  
 Group 2: Dogs with confirmed disease other than AP. These dogs may have had pancreatic 
inflammation but was considered inconsequential and not the primary cause of their clinical 
presentation.  
4.3 Results 
Samples were collected from 64 client-owned dogs, with 26 dogs excluded as no definitive 
diagnosis could be made, leaving 38 dogs for analysis (Figure 4.1). Vomiting was present in 28 
(74%), diarrhea in 8 (21%), abdominal pain in 33 (87%) and abdominal distension in 7 dogs 
(18%) (Table 4.1). No sample on testing had an indeterminate SNAP cPL result. Serum was 
available for Spec cPL measurement in 36 of 38 dogs. Twenty-nine (76%) of these samples 
were either haemolysed {n= 25/38 (66%)}, icteric {n = 3/38 (8%)} or lipaemic {n = 6/38 (16%)}, 
or had a combination of these characteristics {n = 6/38 (16%)}.  
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Figure 4.1 Flow diagram of dogs presented for acute abdomen and their corresponding 
SNAP cPL and subsequent specific canine pancreatic lipase (Spec cPL) tests. Dogs were then 
grouped by either a clinical diagnosis of pancreatitis or other primary disease. 
 
Eleven dogs were diagnosed with AP (Group 1). Breeds in this group included Australian Cattle 
Dog (n=2), Fox terrier (n=1), Border Collie (n=1), Jack Russell terrier (n=1), Labrador (n=1), 
Maltese cross (n=1), Akita (n=1), Siberian Husky (n=1), Miniature Schnauzer (n=1) and Cocker 
Spaniel Cross (n=1). Ages ranged from 1.5 to 13 years (median = 9 years, mean = 8 years). 
There were 7 females (6 neutered), and 4 males (3 neutered). Abdominal ultrasonography was 
consistent with AP in all 11 dogs, and no dog underwent surgery. Three dogs were 
euthanatized (post mortem confirmed diagnosis in 1; no post-mortem examination was 
permitted in 2), with no clinical recurrence in the surviving 8 dogs at 6 months follow-up. No dog  
Definitive diagnosis n = 38 
Clinical diagnosis not pancreatitis 
n = 27 
SNAP cPL 
positive n = 11 
SNAP cPL 
positive n = 9 
 
Spec cPL  
< 200 µg/L     
n = 0 
SNAP cPL 
performed 
all dogs     
n = 38 
Dogs presenting with 
acute abdomen n = 64 
Spec cPL  ≥ 
200 µg/L         
n = 8 
 (7/8 ≥ 400 
µg/L) 
Spec cPL  
< 200 µg/L 
n = 2 
Spec cPL  ≥ 
200 µg/L 
n = 0 
Excluded as 
no definitive 
diagnosis 
reached          
n = 26 
Clinical diagnosis pancreatitis   
n = 11 
SNAP cPL 
negative n = 2 
SNAP cPL 
negative   n = 16 
Spec cPL 
performed 
n = 8 
Spec cPL 
performed 
n = 10 
Spec cPL 
performed 
n = 2 
Spec cPL 
performed 
n = 16 
Spec cPL  
< 200 
µg/L 
n = 4 
Spec cPL  
< 200 µg/L 
n = 16 
Spec cPL  ≥ 
200 µg/L  
n = 0 
Spec cPL  ≥ 
200 µg/L n = 
6 
(6/6 ≥ 400 
µg/L) 
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Table 4.1: Presenting clinical and clinicopathologic characteristics of 38 dogs presenting with 
acute abdominal disease grouped by a clinical diagnosis of acute pancreatitis (Group 1) or 
disease other than acute pancreatitis (Group 2) and their corresponding SNAP canine 
pancreatic lipase (cPL) results.   
 
with AP had azotemia. Abdominal effusions were noted in 5 (45%) of these dogs, but no 
abdominal fluid was collected for analysis. 
 
Primary disease other than AP was diagnosed in 27 dogs (Group 2). Breeds included Labrador 
(n=3), Siberian Husky (n=2), Border Collie (n=2), Rottweiler (n=2), German shepherd (n=2), and 
the remaining 16 dogs were represented by single or mixed breeds. Ages ranged from 17 
weeks to 15 years (median = 10 years; mean = 9 years). There were 9 neutered females, 3 
entire females, 12 neutered males and 3 entire males. Fifteen of these dogs were euthanatized, 
and 1 dog died.  
 
Five of the dogs from group 2 had full post mortem performed, which confirmed the absence of 
pancreatic or peri-pancreatic inflammation or necrosis. Diagnoses included anaplastic large T-
cell lymphoma of the liver (n=1); small intestinal infarction with bilateral adrenomegaly (n=1); 
pancreatic islet cell carcinoma with erosive enterocolitis (n=1); pancreatic islet cell carcinoma 
with hepatic metastasis (n=1); pancreatic carcinoma with hepatic, duodenal, lymph node and 
Parameter Group 1 (Pancreatitis) Group 2 (Not pancreatitis) 
SNAP cPL 
abnormal 
(n = 9) 
SNAP cPL 
normal 
(n = 2) 
SNAP cPL 
abnormal 
(n = 11) 
SNAP cPL 
normal 
(n = 16) 
Vomiting 9 2 7 10 
Diarrhea 2 1 2 3 
Abdominal pain 8 1 9 14 
Abdominal distension 1 0 2 3 
Gross hemolysis 7 1 5 12 
Gross lipemia 2 2 1 1 
Gross icterus 2 0 1 0 
Hyperbilirubinemia 3 0 0 1 
Hypercholesterolemia 5 1 1 2 
Azotaemia 0 0 3 0 
Elevated urea  1 0 2 2 
Abdominal Effusions 
Septic or Inflammatory 
Transudate 
Hemorrhagic 
Not classified 
 
0 
0 
0 
5 
 
0 
0 
0 
0 
 
6 
1 
1 
1 
 
3 
1 
3 
1 
Mortality 
Died 
Euthanatized 
 
0 
3 
 
0 
0 
 
0 
7 
 
1 
8 
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lung metastasis (n=1). Of the 3 dogs with pancreatic islet cell carcinoma, histology did not 
identify inflammation or necrosis associated with pancreatic tissue, although in 1 there was 
virtually no recognisable pancreatic tissue present. None of the dogs with pancreatic carcinoma 
tested positive with either SNAP cPL or Spec cPL. Both remaining dogs had abnormal SNAP 
cPL tests but only the dog with small intestinal infarction had an elevated Spec cPL consistent 
with pancreatitis. 
 
The 22 dogs that did not have post-mortem examination in group 2 were diagnosed with small 
intestinal foreign bodies (n=6), hemoperitoneum due to splenic and/or concurrent hepatic 
masses (n= 3), pyometra (n=2), hepatic abscessation (n=2), emphysematous cholecystitis 
(n=2), abdominal mass and concurrent septic peritonitis (n=1), large solitary hepatic mass 
invading the caudal vena cava (n=1), septic peritonitis due to a ruptured jejunal mass (n=1), 
septic peritonitis due to intestinal foreign body (n=1), prostatic abscessation (n=1), pericardial 
effusion (n=1), and hepatic lymphoma (n=1).  
 
Abdominal ultrasound by a veterinary radiologist was performed in a total 14 dogs of group 2. 
Abdominal surgery was performed in 14 dogs in group 2, of which 8 dogs did not undergo 
abdominal ultrasonography prior. One dog had abdominal and thoracic computed tomographic 
examination. No surgery or specialist abdominal imaging was performed in 4 dogs of group 2.  
A final diagnosis of hemoperitoneum was confirmed in 3 of the 4 by abdominocentesis. All 3 had 
large abdominal masses as ultrasounded by the emergency resident, and were reported as 
splenic (n=2) or hepatic (n=1). The dog identified as having a hepatic mass also displayed a 
septic component as evidenced by intracellular bacteria by cytology.  The remaining dog had a 
post-mortem only. The final diagnosis was pancreatic carcinoma with hepatic metastasis. 
 
In the 11 dogs of group 1, 9 (82%) tested positive with SNAP cPL and 2 (18%) tested negative 
(Table 4.2).  Pancreatic lipase was measured in 8 of 9 positive SNAP dogs, and 100% (8/8) had 
Spec cPL concentrations ≥ 200 µg/L (range 320 to 1000 µg/L; median 800 µg/L; mean 748 
µg/L). There was insufficient serum for Spec cPL testing in the remaining dog. The two dogs 
with negative SNAP cPL results both had Spec cPL concentrations of 30 µg/L.  
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Table 4.2: Specific canine pancreatic lipase (Spec cPL) serum concentrations in 11 dogs 
presenting for acute abdomen with a diagnosis of primary pancreatitis grouped by SNAP cPL 
result (positive or negative) and listed in ascending order by Spec cPL concentration.  
Spec-cPL result (µg/L) n= 11 
Dog  SNAP cPL positive Dog  SNAP cPL negative  
1 Insufficient sample 10 30 
2 320 11 30 
3 504   
4 582   
5 612   
6 969   
7 1000   
8 1000   
9 1000   
 
In the 27 dogs of group 2, 11 (41%) tested positive with SNAP cPL and 16 (59%) tested 
negative (Table 4.3). Pancreatic lipase was measured in 10 of 11 positive SNAP dogs, and 6 
had  Spec cPL concentrations ≥ 400 µg/L, and 4 had Spec cPL < 200 µg/L. There was 
insufficient serum for Spec cPL testing in one SNAP positive dog in group 2. The remaining 16 
dogs in group 2 with a negative SNAP cPL all had Spec cPL concentration < 200 µg/L (median 
30 µg/L, mean 51 µg/L, range 30 to 121 µg/L). Eight of the 11 dogs (73%) with a positive SNAP 
cPL in group 2 had abdominal effusions (septic/inflammatory in 6). In the 16 dogs with a 
negative SNAP cPL in group 2, 8 (50%) had abdominal effusions (with 3 being 
septic/inflammatory). Therefore 9/27 (33%) of dogs in group 2 had septic or inflammatory 
abdominal effusions, with 6 of these 9 having a positive SNAP cPL. Of the 4 dogs with positive 
SNAP cPL and normal Spec cPL results, 2 (50%) had septic or inflammatory abdominal 
effusions. 
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Table 4.3: Diagnosis and specific canine pancreatic lipase (Spec cPL) serum concentration 
(g/L) in 27 dogs presenting for acute abdomen where pancreatitis was not the primary cause 
for presentation, grouped by SNAP cPL result (positive or negative) and listed by organ system 
involved. * Pancreatic histology and post mortem were performed and no pancreatic 
inflammation was present. 
 SNAP cPL positive  SNAP cPL negative 
Dog  Diagnosis Spec 
cPL  
Dog  Diagnosis Spec 
cPL  
1 Small intestinal foreign body No 
sample 
12 Small intestinal foreign body 30 
2 Small intestinal foreign body 30 13 Small intestinal foreign body 30 
3 Small intestinal foreign body 
and septic peritonitis 
105 14 Small intestinal foreign body 30 
4 Small intestinal infarction with 
bilateral adrenomegaly* 
568* 15 Small intestinal foreign body 78 
5 Hepatic T-cell lymphoma* 68* 16 Jejunal mass  (septic) 121 
6 Hepatic mass 404 17 Hepatic lymphoma 30 
7 Hepatic masses / septic 
peritonitis 
672 18 Hemoperitoneum / splenic 
mass 
30 
8 Hepatic/splenic masses  with 
hemoperitoneum 
720 19 Hemoperitoneum / splenic 
mass 
30 
9 Hepatic abscess 1000 20 Emphysematous 
cholecystitis 
30 
10 Hemoperitoneum / septic 
peritonitis 
550 21 Emphysematous 
cholecystitis 
30 
11 Pyometra and septic 
peritonitis 
 30 22 Pyometra 30 
   23 Pericardial effusion 30 
   24 Prostatic abscess 86 
   25 Pancreatic carcinoma*  30* 
   26 Pancreatic carcinoma with 
ulcerative enterocolitis* 
83* 
   27 Pancreatic carcinoma with 
hemoperitoneum* 
121* 
 
Azotaemia was present in 3 dogs in group 2, with creatinine ranging from 220 to 323 µmol/L 
(ref: 44-159 µmol/L) and urea ranging from 10 to 28.2 mmol/L (ref: 2.5-9.6 mmol/L). These 3 
dogs all had positive SNAP cPL results, with 2/3 also having Spec cPL concentration ≥ 200 
µg/L. Urea alone was increased in 4 dogs in this group ranging from 10.1 to 26.9 mmol/L (ref: 
2.5-9.6 mmol/L). Only 2 of these dogs (50%) had a positive SNAP cPL test, and none had Spec 
cPL ≥ 200 µg/L. 
 
The clinical sensitivity and specificity for SNAP cPL was 82% (9/11 dogs of group 1) and 59% 
(16/27 dogs of group 2), respectively. The clinical sensitivity and specificity for Spec cPL was 
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70% (7/10 dogs of group 1) and 77% (20/26 dogs of group 2), respectively. Accuracy of the 
SNAP and Spec cPL with a clinical diagnosis of AP was 66% and 75% respectively. 
 
The agreement of SNAP cPL with a clinical diagnosis of primary AP in all dogs (Table 4.4) 
resulted in a  of 0.33 (95% CI: 0.06-0.61).  
 
Table 4.4: Cross-tabulation of the agreement () between a clinical diagnosis of pancreatitis 
(Group 1) and SNAP cPL for 38 dogs presented with signs of acute abdominal disease (Groups 
1 and 2). 
 Group 1 Group 2 
SNAP positive 9 11 
SNAP negative 2 16 
 
 = 0.33 (95% CI: 0.06-0.61) 
 
Agreement was also calculated to assume the 2 dogs in group 1 that tested normal on SNAP 
cPL were falsely diagnosed with pancreatitis. If these dogs were moved to group 2 for analysis, 
agreement of SNAP cPL and a clinical diagnosis of AP resulted in a  of 0.44 for all dogs (95% 
CI: 0.20-0.67). The agreement of Spec cPL with a clinical diagnosis of primary AP (Table 4.5) in 
all dogs resulted in a  of 0.43 (95% CI: 0.12-0.74). 
 
Table 4.5: Cross-tabulation of the agreement () between a clinical diagnosis of pancreatitis 
(Group 1) and specific canine pancreatic lipase (Spec cPL) for 36 dogs presented with signs of 
acute abdominal disease (Groups 1 and 2). 
 Group 1 Group 2 
Spec cPL ≥ 400 µg/L  7 6 
Spec cPL < 400 µg/L 3 20 
 
 = 0.43 (95% CI: 0.12-0.74) 
 
The agreement between SNAP cPL and Spec cPL
 
for all dogs (Table 4.6) resulted in a  of 0.78 
(95% CI: 0.59-0.98).  
 
 
 
60 
 
Table 4.6: Cross-tabulation of the agreement () between SNAP cPL and specific canine 
pancreatic lipase (Spec cPL) for 36 dogs presented with signs of acute abdominal disease. 
 Spec cPL ≥ 200 µg/L Spec cPL  < 200 µg/L 
SNAP positive 14 4 
SNAP negative 0 18 
 
 = 0.78 (95% CI: 0.59-0.98) 
 
The agreement between SNAP cPL and Spec cPL
 
concentration for dogs with disease of non-
pancreatic origin resulted in  0.65 (95% CI: 0.35-0.94). The agreement between SNAP cPL 
with Spec cPL concentrations in dogs with primary AP resulted in  =1.0.  
 
4.4 Discussion 
This study has demonstrated that SNAP and Spec cPL tests have poor agreement with a 
clinical diagnosis of primary acute pancreatitis in dogs presenting with compatible history and 
clinical signs. This was predominantly due to the tests returning a large number of clinically 
relevant false positives (SNAP cPL: 11/27 dogs or 41%, Spec cPL: 6/26 dogs or 23%).  
 
Sixty percent of SNAP positive dogs without AP had Spec cPL concentrations greater than 400 
µg/L, with no dogs having a value between 200-400 µg/L. In this study, having a second 
reference spot in the SNAP cPL test to indicate concentrations above 400 µg/L would not have 
improved specificity. The specificity of Spec cPL was greater than SNAP cPL. This was 
because 4 dogs without AP had visually abnormal SNAP cPLs, but Spec cPL concentrations 
well below 200 µg/L. The specificity of SNAP cPL and Spec cPL in this study is lower than 
previously reported (Newman et al., 2004; Trivedi et al., 2011; McCord et al., 2012; Mansfield et 
al., 2012). The authors feel this is probably due to a population of exclusively sick dogs with 
similar clinical presentations being tested, without reliance on histologic diagnosis and a known 
final diagnosis. 
 
The sensitivity of the Spec cPL is consistent with that reported previously (Newman et al., 2004; 
Steiner et al., 2008; Trivedi et al., 2011; Neilson-Carley et al., 2011,) although that of the SNAP 
cPL was lower (McCord et al., 2012). There were only a small number of false negatives (2/11 
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dogs or 18%) with the  SNAP cPL. The sensitivity of Spec cPL was lower than SNAP cPL due to 
1 dog with a cPL concentration of 320 µg/L being below the diagnostic cut-off of 400 µg/L. 
 
There was good agreement between SNAP cPL and Spec cPL results. This was greater in dogs 
with a clinical diagnosis of primary pancreatitis than in those without. Further, all dogs testing 
normal on SNAP cPL had Spec cPL concentrations below 200 µg/L (18/18 dogs or 100%).  
 
There are several possible explanations for the 11/27 dogs without AP that tested positive with 
SNAP cPL. One possible explanation is that pancreatic inflammation may develop due to diffuse 
abdominal inflammation, as found in dogs with septic peritonitis.  Additionally, any condition that 
causes hypoperfusion of the pancreas, or ischemia and reperfusion of the splanchnic circulation 
may cause pancreatic inflammation, as the pancreas is exquisitely sensitive to disturbances of 
microcirculation (Cuthbertson et al., 2006). Increased total serum lipase activity has been 
reported in dogs with duodenal foreign bodies (Willard et al., 1993) and acute gastroenteritis 
(Rallis et al., 1996). This may potentially be due to production of lipase by organs other than the 
pancreas, or due to duodenal reflux causing sub-clinical pancreatitis. In studies that have 
assessed specificity of cPL, diagnosis was based on post-mortem analysis from referral centers 
(Trivedi et al., 2011; Mansfield et al., 2012) and dogs with intestinal foreign bodies were not 
included in the sample populations. Therefore it is remains unclear whether cPL concentrations 
are increased in dogs with duodenal foreign bodies. However, none of the dogs with intestinal 
foreign bodies in this study had elevated Spec cPL, and only 2 were reported in the duodenum. 
It is possible that other isoforms of lipase were being measured. This is considered unlikely as 
pancreatic lipase has been localized to the pancreas in immunohistochemical studies (Steiner et 
al., 2002),
 
and is too low to be quantified in dogs with exocrine pancreatic insufficiency (Steiner 
et al., 2006). 
 
Dogs with decreased renal function have been shown to have increased serum total lipase 
activities (Strombeck et al., 1981; Mansfield et al., 2000). One study has shown that Spec cPL is 
not increased in dogs with experimentally induced chronic renal failure (Steiner et al., 2010), but 
this has not been verified in dogs where there may be a naturally occurring acute decline in 
glomerular filtration. In the study cohort reported here there were 3 dogs with azotemia, 
although none had anuric renal failure. These 3 dogs were not diagnosed with AP, but all had 
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positive SNAP cPL results, and 2 also had Spec cPL concentrations ≥ 200 µg/L. The clinical 
diagnoses in these 3 azotemic dogs were splenic and hepatic masses with hemoperitoneum, 
septic peritonitis secondary to a perforating intestinal foreign body, and small intestinal 
thrombosis. The dog with intestinal thrombosis underwent post-mortem examination and no 
histological evidence of pancreatitis was present. The remaining 2 dogs underwent abdominal 
surgery with no gross evidence of pancreatitis recorded in the surgical reports. However, 
histological examination of the pancreas was not performed and therefore concurrent 
microscopic pancreatitis could not be ruled out.  Additional studies are required to further 
elucidate the role of azotemia on cPL concentrations, particularly in acute disease. 
 
All 3 dogs with pancreatic carcinoma had negative SNAP cPL and Spec cPL results. This may 
be due to very little associated inflammation, as documented in two dogs, or a lack of functional 
pancreatic tissue, as observed in the remaining dog.   
 
Four dogs in this study had positive SNAP cPL results but Spec cPL concentrations < 200 µg/L. 
Operator error in interpreting the SNAP cPL results is a possible explanation for this 
discrepancy, but is considered unlikely. All 3 individuals interpreting the test were trained 
personnel, and made the observations after performing the test strictly according to the 
manufacturer guidelines.  The manufacturer reports 96-100% agreement between SNAP cPL 
and Spec cPL for normal samples (cPL < 200 µg/L) and 88-92% agreement for abnormal 
samples (cPL ≥200 µg/L) (Steiner et al., 2001). It is also reported that visual discrepancy occurs 
mostly at Spec cPL concentrations around 200 µg/L. For the 4 discrepant results, SNAP cPL 
was abnormal, but all had Spec cPL concentrations < 105 µg/L. This makes visual discrepancy 
unlikely. Prolonged storage of serum samples prior to measurement of Spec cPL may also be a 
contributing factor, as all 4 of these samples were frozen for greater than 6 months. The stability 
of Spec cPL has been reported to be unchanged after 21 days at room temperature, 
refrigerated, at -20°C, and at -80°C (Steiner et al., 2009). Additionally, a study evaluating lipase 
activity and Spec cPL in dogs with experimentally induced chronic renal failure utilized stored 
samples that were more than 20 years old, and demonstrated significantly elevated pancreatic 
lipase concentrations in one dog (Steiner et al., 2010). Instability of canine pancreatic lipase in 
serum frozen at -20˚C is therefore thought to be an unlikely cause of the discrepancies in this 
study. 
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Hemolysis, icterus and lipemia were frequently present in the samples in this study, but these 
factors have been shown not to interfere with the visual interpretation of SNAP cPL (Steiner et 
al., 2001)
 
tests or with measurement of Spec cPL concentrations (Huth et al., 2010).
 
It is 
theoretically possible that an unknown protein was present in the serum of these 4 dogs that 
caused interference.  However, given that both SNAP cPL and Spec cPL utilize the same dual 
monoclonal antibodies, abnormal results would be expected for both tests if cross-reactivity was 
present. However, the stability of a potential cross-reacting inflammatory protein may not be as 
long lived during storage as cPL, and not be detectable at the time of Spec cPL measurement. 
  
One limitation of this study is the use of ultrasound alone to diagnose AP. The diagnosis of AP 
by ultrasound has been reported to have a sensitivity ranging from 66 to 68% (Hess et al.,1998; 
Steiner et al., 2008). In these studies, there may have been primary disease other than AP as 
no final diagnosis was discussed, and mild or chronic forms of pancreatitis could also have been 
present, reducing the sensitivity of ultrasound (Steiner et al., 2008). The other study evaluating 
ultrasound detection of pancreatitis was performed between 1986 and 1995, commencing well 
over 20 years ago (Hess et al.,1998). The authors believe the diagnostic sensitivity of 
ultrasound is likely to be much higher now than in the earlier studies due to improved equipment 
and operator expertise. Additionally, the specificity of ultrasound for the diagnosis of AP due to 
the presence of hyperechogencity associated with peri-pancreatic fat necrosis is well accepted 
(Mansfield et al., 2011). Therefore,
 
the authors feel that the number of false positives in dogs 
diagnosed with primary AP were negligible.
 
A further limitation was the absence of 
ultrasonographic evaluation of the pancreas in nearly half of the dogs of group 2. This may have 
enabled comparison between the positive tests of group 2 and ultrasonographic findings. All 
dogs in the AP group were treated appropriately for AP, and had no recurrence of clinical signs 
within 6 months of discharge for all survivors, making concurrent pancreatic neoplasia or other 
abdominal disease such as septic peritonitis unlikely. Of the 3 dogs in this group that were 
euthanatized, consent for post-mortem examination was only given for 1 dog. This confirmed 
the presence of severe pancreatic inflammation and necrosis. To determine if a false positive 
diagnosis of AP may have influenced this agreement, dogs in group 1 that had a negative 
SNAP cPL / Spec cPL test were moved to group 2 for analysis. Analysis of agreement for a 
clinical diagnosis of pancreatitis then gave a  of 0.44, which still represents poor agreement.  
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A further limitation of this study was the small number of dogs analyzed. Many dogs were 
excluded due to an absence of a definitive diagnosis. Therefore, bias towards severe disease 
may have arisen as dogs with mild pancreatitis may not have had a diagnosis made after full 
diagnostic work-up. It is unknown what effect inclusion of those dogs would have on the 
analysis of diagnostic accuracy, sensitivity or specificity. 
The manufacturer currently recommends performing a quantitative Spec cPL assay following 
SNAP cPL at initial presentation. Although there was a good concordance between SNAP cPL 
and Spec cPL concentration overall in this study, there was some discordance in dogs without 
primary AP. However, the use of additional testing such as abdominal imaging, along with 
stringent assessment of clinical and historical findings to make a diagnosis of acute pancreatitis 
may preclude the necessity of follow-up testing. Currently there is no published data that shows 
changes in serum concentrations of pancreatic enzymes corresponds to clinical improvement, 
or should be used to select treatment regimes.  
 
4.5 Conclusion  
 
This study indicated a poorer specificity of cPL for diagnosing AP than previously reported, 
although sensitivity was similar. There was reasonable agreement between SNAP cPL and 
Spec cPL results. Measurement of Spec cPL had a better agreement than SNAP cPL for a 
clinical diagnosis of AP, but overall both produced poor agreement. A positive SNAP cPL or 
Spec cPL may be indicative of pancreatic inflammation, however this cannot readily determine 
the primary reason for clinical presentation. Conversely, a negative SNAP cPL or Spec cPL < 
200 µg/L appears to be moderately specific, with a small number of dogs (2/11; 18%) diagnosed 
with AP having false negative results. 
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Chapter 5: GENERAL DISCUSSION 
 
The complicated challenges of determining test accuracy for the diagnosis of acute pancreatitis 
were highlighted and discussed in Chapter 3 of this thesis. Historically, these challenges related 
to the difficulty of creating good study design in an appropriate clinical setting for acute 
pancreatitis. The prospective study that was conducted (Chapter 4) was designed in an attempt 
to address some of these issues, and resulted in highlighting others. The aim of this final 
chapter is to reflect on, and critically evaluate, the study design described in Chapter 4, and to 
provide further discussion on the problems encountered therein.  
One of the common problems encountered by previous studies has been the failure to select an 
appropriate sample population; firstly lack of an adequate sample size, and secondly the 
selection of a biased population. This study has also suffered from both of these challenges.  
The inclusion criteria for this study, reported in Chapter 4, limited the population to subjects 
where a full diagnostic work-up was performed; this may have not only constrained the sample 
number, but may have also introduced bias by skewing the selected population towards 
subjects with more severe disease. The setting for the study was a 24-hour referral hospital, 
which may have further skewed the population to the more severe end of the spectrum of 
disease. If the population includes mostly severely affected subjects, then the sensitivity may be 
falsely increased and specificity falsely decreased. In this study, the sensitivity of the SNAP
®
 
cPL test was similar to other studies, but its specificity was much lower, which may reflect this 
bias.  Despite these limitations in sample population, it is suggested that the selection of the 
population used in this study was more appropriate than previous studies, as it included those 
with the disease and those with similar clinical signs but without the disease. This falls more 
closely towards the ‘intended use’ population, although, as mentioned above, it is still likely 
skewed with regard to severity of disease.  
The accepted gold standard of histopathological diagnosis cannot be achieved for a cohort of 
dogs that are mostly expected to survive. As mentioned previously, even if necropsy is applied 
to the cohort, there is still the concern about whether the current grading system is too stringent 
for defining pancreatitis. But further controversy also exists as to whether histopathology should 
be used at all as the gold standard of diagnosing the syndrome of acute pancreatitis. This study 
highlighted this controversy by abandoning a gold standard altogether, and using a composite 
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reference standard instead. This approach was chosen not only due to the lack of availability of 
histopathology within the cohort, but because it was deemed to be a more appropriate method 
for determining Spec cPL® accuracy. As such, this is the first study to separate acute 
pancreatitis into two different categories; primary and secondary. The historical gold standard 
would not have been useful in separating these two diagnoses; only a composite of diagnostic 
tests and expert opinion can be used in this clinical setting. Therefore, the choice of a composite 
reference standard in this study was purposeful and, in the author’s opinion, more useful. It was 
not a goal of the study to disprove that increased cPL indicated pancreatic inflammation, rather 
that increased cPL did not rule out another, more important, underlying disease. In these cases 
of secondary pancreatitis, the cPL result was considered to be irrelevant, or not necessarily 
helpful, as there was other significant underlying disease. By way of analogy, an increased 
alanine transferase activity does not simply indicate that hepatitis is the diagnosis, but that there 
may be other reasons for leakage of this enzyme. This study has tried to shift the emphasis 
towards the ‘clinical interpretation’ of the result. This may be another reason why specificity was 
much lower in this study compared to previous reports, as the dogs categorised as being 
‘disease-negative’ may still have had pancreatic inflammation.  
During this study, considerable reliance was placed on ultrasound examination as an inclusion 
into the composite reference standard. It is the author’s opinion that the exclusion of ultrasound 
examination in the current gold standard of diagnosis, and reliance on histopathology instead, 
may have been premature. Since the landmark report for sonographic sensitivity of canine 
pancreatitis was undertaken nearly 30 years ago (Hess et al., 1998), the ultrasound equipment, 
operator skills and operator knowledge have most likely vastly improved the accepted sensitivity 
now. In fact, clinicians currently use ultrasonography as the test of choice for the clinical 
diagnosis of acute pancreatitis. Focus should be given to providing evidence that modern 
ultrasonography is a useful tool for diagnosing pancreatitis.  
As there is currently no consensus on what elements should be included in a composite 
reference standard, it brings into question the validity of using certain statistical tests in order to 
make any comment about accuracy of the Spec cPL® . This study included sensitivity, 
specificity and kappa agreement to describe the relationship between primary acute pancreatitis 
and cPL. Strictly, sensitivity and specificity should not be applied where an accepted gold 
standard has not been used as the comparison. These operational characteristics were included 
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in this study (Chapter 4) to provide a comparison to the previous reports in literature and to 
satisfy the needs of the veterinary audience in this regard. However, in reality the study used a 
composite reference standard and defined the disease as a clinical syndrome. Without the 
absolute knowledge of the presence or absence of pancreatitis, it may have been inappropriate 
to report sensitivity and specificity.  
This concept of purposefully avoiding sensitivity and specificity was discussed briefly in Chapter 
3, and using agreement as the alternative test may have been a better option for this study. 
Certainly it was appropriate for describing the relationship between Spec cPL
®
 and SNAP
®
 cPL. 
The use of this test for describing the accuracy of the Spec cPL
®
  and SNAP
®
 cPL for diagnosis 
of primary pancreatitis is likely a controversial decision. However, it was felt by the authors that 
sensitivity and specificity might be misinterpreted by the audience as reflective of the test’s 
accuracy for detecting pancreatic inflammation, not simply agreement with a clinical diagnosis. 
As it is more important in critically ill patients to distinguish between primary and secondary 
pancreatitis, choice of a composite reference standard and use of agreement as expression of 
the accuracy was felt to be the best method to display the Spec cPL
®
’s and SNAP
®
 cPL’s 
limitations in the clinical setting. 
 
Conclusion 
The evidence from the study undertaken here highlights the difficulties in utilising a serum 
marker for the diagnosis of canine acute pancreatitis. Indeed, the use of any single test in the 
diagnosis of acute pancreatitis is difficult to recommend. While further investigations of cPL and 
other serum markers are likely to be undertaken, the value of including other diagnostic 
modalities such as abdominal ultrasound should be revisited. However, the lack of a universal 
gold standard is expected to remain unchanged in ante-mortem diagnosis in the near future, 
which is likely to continue to generate much controversy surrounding the diagnosis of this 
important canine disease. 
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